<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
         xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         dtd-version="1.1"
         xml:lang="sl"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Zdravniški vestnik</journal-title>
            <trans-title-group xml:lang="en">
               <trans-title>Slovenian Medical Journal</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2633</article-id>
         <article-id pub-id-type="publisher-id">2633</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Human reproduction</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Reprodukcija človeka</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Original scientific article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Izvirni znanstveni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject>Reprodukcija človeka</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl">Predoperacijsko zdravljenje miomov z ulipristal acetatom</article-title>
            <trans-title-group>
               <trans-title xml:lang="en">Preoperative treatment of uterine leiomyomas with ulipristal acetate</trans-title>
            </trans-title-group>
            <alt-title alt-title-type="running-head" xml:lang="sl">Predoperacijsko zdravljenje miomov z ulipristal acetatom</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Vogler</surname>
                  <given-names>Andrej</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Rajić</surname>
                  <given-names>Mišo</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
         </contrib-group>
         <aff-alternatives id="aff1">
            <aff xml:lang="sl">
               <label>1</label>
               <institution>Klinični oddelek za reprodukcijo, Ginekološka klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>1</label>
               <institution>Department of Human Reproduction, Division of Gynaecology, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Andrej Vogler, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>12</month>
            <year>2018</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>12</month>
            <year>2018</year>
         </pub-date>
         <volume>87</volume>
         <issue>11–12</issue>
         <fpage>509</fpage>
         <lpage>18</lpage>
         <history>
            <date date-type="received">
               <day>4</day>
               <month>7</month>
               <year>2017</year>
            </date>
            <date date-type="accepted">
               <day>31</day>
               <month>10</month>
               <year>2018</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2018, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2018, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2018</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="sl">
            <title>Izvleček</title>
            <p>Izhodišče: Miomi so najpogostejši benigni tumorji maternice. Približno petina do polovica žensk z miomi ima simptome oz. pri njih miomi hitro rastejo. Najpogosteje gre za podaljšane in/ali močne menstruacijske krvavitve, ki povzroče anemijo, dismenorejo, bolečine zaradi pritiska na sosednje organe, redkeje pa neplodnost in motnje pri odvajanju urina in blata. Zdravljenje miomov je potrebno pri bolnicah s simptomi in v primeru, ko gre za hitro rastoče miome. Selektivni modulatorji progesteronskih receptorjev (SMPR) so novejša zdravila za predoperacijsko zdravljenje miomov, ki le-te učinkovito zmanjšajo, povzročijo amenorejo ali zmanjšanje krvavitev, s tem pa izboljšajo krvno sliko. Namen raziskave je bil ugotoviti vpliv predoperacijskega zdravljenja s SMPR ulipristal acetatom (UPA) na velikost miomov in krvno sliko.</p>
            <p>Metode: Petdesetim (50) bolnicam s simptomatskimi miomi smo pred načrtovanim kirurškim posegom predpisali SMPR UPA 5 mg za dvanajst tednov. Pred in po končanem zdravljenju smo izmerili velikost miomov, ocenili količino krvavitve iz maternice in preverili krvno sliko.</p>
            <p>Rezultati: Po končanem zdravljenju z UPA se je povprečna prostornina največjega mioma zmanjšala za 33,3 %, skupna povprečna prostornina do 3 največjih miomov pa za 32,3 %. Zmanjšanje prostornine je bilo v obeh primerih statistično značilno. Amenoroičnih je bilo 41 (82,0 %) bolnic, pri 9 (18,0 %) pa so se menstruacijske krvavitve znatno zmanjšale. Pri vseh bolnicah smo opazili porast koncentracije hemoglobina.</p>
            <p>Zaključek: 12-tedensko predoperacijsko zdravljenje z UPA učinkovito zmanjša velikost miomov in s tem olajša oziroma omogoči najsodobnejše laparoskopsko kirurško zdravljenje. Ker povzroči amenorejo oziroma zmanjša količino menstruacijske krvavitve, se izboljša tudi krvna slika, kar je pomembno za okrevanje po operaciji.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>Abstract</title>
            <p>Background: Uterine leiomyomas are the most common benign uterine tumours in women. They are symptomatic in 20 to 50 % of cases. Symptoms associated with leiomyomas include heavy, prolonged menstrual bleeding leading to anaemia, dysmenorrhoea, pelvic pressure and pain, impaired function of adjacent organs, such as bladder and bowel, and reproduction dysfunction. Options for medical therapy are currently limited to preoperative reduction of symptoms related to uterine bleeding and fibroid size. Recently, selective progesterone receptor modulators (SPRM) have been introduced and approved in preoperative treatment of leiomyomas. The aim of our study was to assess the efficacy of preoperative treatment with SPRM ulipristal acetate (UPA) on leiomyoma shrinkage and haemoglobin (Hb) concentration improvement.</p>
            <p>Methods: Fifty patients with symptomatic leiomyomas were assigned for preoperative treatment with 5 mg of UPA daily for 12 weeks. Before and a week after the UPA treatment was completed, leiomyoma volume was measured, and Hb concentrations and the amount of uterine bleeding were assessed. The outcomes were changes from baseline in leiomyoma volume and the proportion of patients with controlled bleeding after the treatment.</p>
            <p>Results: After the completion of UPA treatment there was a mean volume reduction of the largest myoma by 33.3 %, whereas the mean volume reduction of up to 3 largest myomas was 32.3 %. Volume reduction was in both cases statistically significant. During the treatment course 41 (82.0 %) women were amenorrhoeic and the other 9 (18.0 %) had a significant reduction in uterine bleeding. The reduction in bleeding was accompanied by improvement in Hb levels in all patients.</p>
            <p>Conclusion: Preoperative treatment with UPA for 12 weeks effectively reduces leiomyoma volume and facilitates or even makes laparoscopic surgery feasible. It is also beneficial for correcting anaemia, which is of outmost importance for postoperative recovery.</p>
         </trans-abstract>
         <kwd-group xml:lang="sl">
            <kwd>miomi</kwd>
            <kwd>medikamentno zdravljenje</kwd>
            <kwd>operacija</kwd>
            <kwd>ulipristal acetat</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <kwd>leiomyoma</kwd>
            <kwd>medical treatment</kwd>
            <kwd>surgery</kwd>
            <kwd>ulipristal acetate</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Uvod">
         <label>1</label>
         <title>Uvod</title>
         <p>Miomi so najpogostejši benigni tumorji maternice, saj jih ima od 30–70 % žensk v rodni dobi (<xref ref-type="bibr" rid="b1">1</xref>). To so monoklonski tumorji gladke mišičnine miometrija in vsebujejo velike količine zunajceličnega matriksa, ki vsebuje kolagen, fibronektin in proteoglikan (<xref ref-type="bibr" rid="b2">2</xref>). Približno petina do polovica žensk z miomi ima simptome, ki negativno vplivajo na zdravje in kakovost življenja. Najpogosteje gre za podaljšane in/ali močne menstruacijske krvavitve, ki povzroče anemijo, dismenorejo, bolečine zaradi pritiska na sosednje organe, redkeje povzroča neplodnost in motnje pri odvajanju urina in blata. Sam nastanek miomov še danes ni povsem pojasnjen, dobro pa je znano, da gre za hormonsko odvisne tumorje. Na rast miomov vplivajo predvsem steroidni hormoni jajčnikov estrogeni in progesteron ter lokalni rastni dejavniki (<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b4">4</xref>).</p>
         <p>Zdravljenje miomov je potrebno pri bolnicah s simptomi in v primerih, ko gre za hitro rastoče miome. Pri ženskah, ki načrtujejo zanositev in imajo sicer miome brez simptomov, pa jih je treba odstraniti, če deformirajo maternično votlino. Zdravila, s katerim bi popolnoma odstranili miome, žal še ne poznamo in ga tudi ne pričakujemo v bližnji prihodnosti (<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b6">6</xref>). Zato sta histerektomija ali samo miomektomija kljub nekaterim nekirurškim možnostim zdravljenja miomov, kot sta embolizacija maternične arterije in z magnetno resonanco vodena žariščna ultrasonografija še vedno najpogostejša načina zdravljenja. Večino bolnic lahko operiramo laparoskopsko ali histeroskopsko, vendar ima tak način tudi omejitve glede na število in velikost miomov oziroma maternice (<xref ref-type="bibr" rid="b7">7</xref>). Medikamentno zdravljenje se običajno omejuje na lajšanje simptomov pred operacijo, predvsem močnih krvavitev in anemije, ter zmanjšanje velikosti miomov (<xref ref-type="bibr" rid="b8">8</xref>). Trenutno so za medikamentno zdravljenje miomov registrirani le agonisti gonadoliberinov (GnRHa) in selektivni modulator progesteronskih receptorjev (SMPR) ulipristal acetat (UPA), ki je v Evropi registriran od leta 2012. GnRHa<italic toggle="yes"> </italic>povzročijo začasno menopavzo. Zaradi padca ravni estrogenov in progesterona se maternica in miomi začasno zmanjšajo, krvavitve pa prenehajo, kar je lahko koristno pred načrtovanim kirurškim zdravljenjem. GnRHa imajo veliko stranskih učinkov zaradi hipoestrogenega stanja, vključno z izgubo kostne mase, zato niso primerni za daljšo uporabo. Manj primerni so tudi za zmanjševanje miomov pred načrtovano miomektomijo, ker se meja med normalnim miometrijem in miomi zabriše (<xref ref-type="bibr" rid="b9">9</xref>,<xref ref-type="bibr" rid="b10">10</xref>,<xref ref-type="bibr" rid="b11">11</xref>).</p>
         <p>SMPR<italic toggle="yes"> </italic>so trenutno verjetno najobetavnejša zdravila za predoperacijsko zdravljenje miomov. Najnovejše raziskave SMPR ulipristal acetata (UPA) pa kažejo tudi na varno dolgotrajnejšo uporabo. Z dolgotrajnejšim zdravljenjem bi se lahko izognili operacijskemu zdravljenju predvsem pri ženskah v predmenopavzi (<xref ref-type="bibr" rid="b12">12</xref>,<xref ref-type="bibr" rid="b13">13</xref>,<xref ref-type="bibr" rid="b14">14</xref>). UPA povzroči apoptozo miomskih celic in tako zmanjša prostornino miomov tudi do 46 %, zavira ovulacijo in s tem povzroči amenorejo pri do 90 % bolnic (<xref ref-type="bibr" rid="b12">12</xref>,<xref ref-type="bibr" rid="b15">15</xref>). UPA ne vpliva na osnovne vrednosti gonadotropnih hormonov in zato ne povzroči hipoestrogenizma (<xref ref-type="bibr" rid="b16">16</xref>). Zdravljenje s SMPR lahko povzroči benigno, nefiziološko, neproliferativno histološko spremembo endometrija, kar se poimenuje <italic toggle="yes">z modulatorji progesteronskih receptorjev povezana sprememba endometrija </italic>(<italic toggle="yes">angl.</italic> progesterone receptor modulator associated endometrial changes, PAEC) (<xref ref-type="bibr" rid="b17">17</xref>,<xref ref-type="bibr" rid="b18">18</xref>). Ta sprememba spontano izzveni v nekaj tednih do mesecih po prenehanju zdravljenja z UPA (<xref ref-type="bibr" rid="b12">12</xref>,<xref ref-type="bibr" rid="b15">15</xref>,<xref ref-type="bibr" rid="b19">19</xref>).</p>
         <p>Namen naše raziskave je bil pridobiti lastna spoznanja z uporabo novega zdravila za predoperacijsko zdravljenje miomov, saj je bilo doslej tovrstnih raziskav zelo malo in so jih večinoma opravili le pri bolnicah z močnimi krvavitvami zaradi miomov, ne pa pri tistih z drugimi simptomi. Zanimal nas je predvsem učinek UPA na zmanjšanje miomov in izboljšanje krvne slike, saj so se dosedanje raziskave osredinile predvsem na zmanjšanje krvavitev in izboljšanje kakovosti življenja.</p>
      </sec>
      <sec id="s2" sec-type="Preiskovanke in metode">
         <label>2</label>
         <title>Preiskovanke in metode</title>
         <sec id="s2.1" sec-type="Preiskovanke in meritve">
            <label>2.1</label>
            <title>Preiskovanke in meritve</title>
            <p>Prospektivno, nerandomizirano raziskavo smo opravili na Kliničnem oddelku za reprodukcijo Ginekološke klinike Univerzitetnega kliničnega centra Ljubljana med oktobrom 2013 in decembrom 2016. Vključili smo 50 bolnic z miomi s simptomi, pri katerih je bilo potrebno zdravljenje z operacijo. Dodatna merila za vključitev so bila še: premer največjega mioma več kot 3 cm in delujoči jajčniki. V raziskavo nismo vključili bolnic po menopavzi, tistih z nepojasnjenimi krvavitvami iz maternice in bolnic, ki so v zadnjih šestih mesecih jemale hormonsko terapijo. Preiskovanke so bile stare 26–57 let (povprečno 43,4 let, SO 7,33).</p>
            <p>Pred načrtovanim operacijskim posegom smo vsem bolnicam predpisali UPA v odmerku 5 mg dnevno za 12 tednov, ki so ga pričele jemati prve 4 dni menstruacije v skladu z navodili o predpisovanju zdravila. Vsem smo pred pričetkom zdravljenja določili koncentracijo hemoglobina (Hb). Anemičnim bolnicam smo dodatno predpisali še pripravek železa v obliki tablet (100 mg železovega (III) oksida dnevno), če jim ga niso predpisali že izbrani zdravniki. Vsem preiskovankam smo pred pričetkom zdravljenja z UPA z ultrazvočno preiskavo (UZ) izmerili 3 največje premere do 3 največjih miomov v 2 ravninah. Iz povprečnega premera smo nato izračunali prostornino do 3 največjih miomov s formulo za prostornino krogle (V = 4/3πr<sup>3</sup>). En do 2 tedna po končanem zdravljenju z UPA smo ponovno opravili enake UZ meritve do 3 največjih miomov in ponovno določili koncentracijo Hb.</p>
            <p>
               <graphic xlink:href="2633-web-resources/image/zdravvestn-2633-sl-01.png"
                        position="float"
                        orientation="portrait"/>
            </p>
            <p>Slika 1: Mediana (1., 3. kvartil, min./maks.) sprememba vsote prostornine do 3 največjih miomov v odstotkih.</p>
            <p>Pri vseh preiskovankah smo opazovali parametre, ki so bili pomembni za oceno uspešnosti predoperacijskega zdravljenja z UPA: spremembo prostornine vseh izmerjenih miomov in največjega mioma, spremembo krvavitev iz maternice med zdravljenjem, spremembo v koncentraciji Hb in zabeležili stranske učinke. Ob koncu zdravljenja smo z ultrazvočno preiskavo ocenili tudi debelino endometrija in ga pri bolnicah, pri katerih smo napravili histerektomijo, tudi histološko pregledali.</p>
            <p>Za uspešno zdravljenje z UPA smo, zaradi možne napake pri meritvah, upoštevali tiste bolnice, pri katerih se je skupna prostornina miomov zmanjšala za najmanj 10 %. Vse bolnice smo 13. do 16. teden po pričetku zdravljenja z UPA laparoskopsko operirali. Vrsto kirurškega posega smo določili glede na število miomov, morebitne operacije zaradi miomov pred tem, starost, željo po zanositvi in željo po ohranitvi maternice. Štirim bolnicam (8,0 %) smo napravili totalno laparoskopsko histerektomijo (TLH), 25 (50,0 %) supracervikalno laparoskopsko histerektomijo (SLH) in 21 (40,0 %) laparoskopsko miomektomijo. Kar 14 (28,0 %) bolnic je želelo po končanem zdravljenju še zanositi, 7 (14,0 %) pa jih je želelo le ohraniti maternico. Pri bolnicah, pri katerih smo odstranili le miome, smo subjektivno ocenili mejo med miomom in miometrijem oziroma težavnost luščenja miomov in njihovo konsistenco.</p>
            <p>Vse ultrazvočne meritve in operacije je opravil prvi avtor članka.</p>
            <p>Ker je v naši raziskavi šlo zgolj za predoperacijsko zdravljenje z registriranim zdravilom za tovrstno zdravljenje, vsi ostali postopki pa so bili rutinski kot pri vseh ostalih bolnicah pred operacijo zaradi miomov maternice, etična ocena raziskave ni bila potrebna.</p>
         </sec>
      </sec>
      <sec id="s3" sec-type="Statistične metode">
         <label>3</label>
         <title>Statistične metode</title>
         <p>Normalnost porazdelitve opazovanih spremenljivk smo preverili s Shapiro-Wilkovim testom. Ker so bile spremenljivke normalno porazdeljene, smo rezultate prikazali kot povprečja s standardnim odklonom (SO). Razliko v prostornini miomov pred in po zdravljenju z UPA ter razliko v koncentraciji Hb pred in po zdravljenju smo testirali s t- testom za odvisna vzorca. Izračunali smo tudi intervale zaupanja. Statistične analize smo opravili s programom Statistica 8.0 (StatSoft Inc.). Prag statistične značilnosti je bil pri p &lt; 0,05.</p>
      </sec>
      <sec id="s4" sec-type="Rezultati">
         <label>4</label>
         <title>Rezultati</title>
         <p>V <xref ref-type="table" rid="table1">Tabeli 1</xref> so prikazane indikacije za operacijsko zdravljenje preiskovank. 14 bolnic (28,0 %) je imelo 1 miom, 9 (18 %) 2 in 27 (54,0 %) 3 ali več miomov. Med 50 bolnicami je bilo 41 (82,0 %) anemičnih s koncentracijo hemoglobina, nižjo od 120 g/l.</p>
         <p>Med jemanjem UPA je bilo 41 (82,0 %) bolnic amenoroičnih, ostalih 9 (18,0 %) pa je imelo le blage ciklične krvavitve.</p>
         <table-wrap position="anchor" id="table1" orientation="portrait">
            <label>Tabela 1:</label>
            <caption>
               <p> Indikacije za operacijsko zdravljenje.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Indikacije</th>
                     <th align="right" rowspan="1" colspan="1">Št. bolnic</th>
                     <th align="right" rowspan="1" colspan="1">%</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Hipermenoreja</td>
                     <td align="right" rowspan="1" colspan="1">17</td>
                     <td align="right" rowspan="1" colspan="1">34,0</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Hipermenoreja in dismenoreja</td>
                     <td align="right" rowspan="1" colspan="1">14</td>
                     <td align="right" rowspan="1" colspan="1">28,0</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Dismenoreja</td>
                     <td align="right" rowspan="1" colspan="1">5</td>
                     <td align="right" rowspan="1" colspan="1">10,0</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Hipermenoreja, dismenoreja, bolečine</td>
                     <td align="right" rowspan="1" colspan="1">4</td>
                     <td align="right" rowspan="1" colspan="1">8,0</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Hipermenoreja, dismenoreja, rastoči miomi</td>
                     <td align="right" rowspan="1" colspan="1">4</td>
                     <td align="right" rowspan="1" colspan="1">8,0</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Rastoči miomi, dismenoreja</td>
                     <td align="right" rowspan="1" colspan="1">2</td>
                     <td align="right" rowspan="1" colspan="1">4,0</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Rastoči miomi, bolečine</td>
                     <td align="right" rowspan="1" colspan="1">4</td>
                     <td align="right" rowspan="1" colspan="1">8,0</td>
                  </tr>
                  <tr>
                     <th rowspan="1" colspan="1">Skupaj</th>
                     <th align="right" rowspan="1" colspan="1">50</th>
                     <th align="right" rowspan="1" colspan="1">100,0</th>
                  </tr>
               </tbody>
            </table>
         </table-wrap>
         <p>Po končanem zdravljenju z UPA se je povprečna prostornina največjega mioma zmanjšala za 33,3 % (95 % IZ [-41,8; -24,9]), skupna povprečna prostornina do 3 največjih miomov pa za 32,3 % (95 % IZ [-41,3; -23,3]). Zmanjšanje prostornine je bilo v obeh primerih statistično značilno (<xref ref-type="table" rid="table2">Tabela 2</xref>).</p>
         <table-wrap position="anchor" id="table2" orientation="portrait">
            <label>Tabela 2:</label>
            <caption>
               <p> Sprememba prostornine največjega mioma in skupne prostornine miomov (50 bolnic) v ml in odstotkih pred pričetkom ter po končanem zdravljenju z UPA. Podatki so izraženi kot povprečje prostornine (standardni odklon) in 95-odstotni interval zaupanja (IZ) za spremembo prostornine v ml ter deležu spremembe v %.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Prostornina miomov</th>
                     <th rowspan="1" colspan="1">Pred UPA (ml)</th>
                     <th rowspan="1" colspan="1">Po UPA (ml)</th>
                     <th rowspan="1" colspan="1">ΔV (ml)</th>
                     <th rowspan="1" colspan="1">95 % IZ <break/>(ΔV ml)</th>
                     <th rowspan="1" colspan="1">p (ΔV ml)</th>
                     <th rowspan="1" colspan="1">ΔV (%)</th>
                     <th rowspan="1" colspan="1">
                        <p>95 % IZ</p>
                        <p>(ΔV %)</p>
                     </th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Največji</td>
                     <td rowspan="1" colspan="1">153,6 (178,0)</td>
                     <td rowspan="1" colspan="1">97,7 (132,6)</td>
                     <td rowspan="1" colspan="1">-56,0 (133,3)</td>
                     <td rowspan="1" colspan="1">[-93,0; -19,1]</td>
                     <td rowspan="1" colspan="1">0,004</td>
                     <td rowspan="1" colspan="1">-33,3 (30,5)</td>
                     <td rowspan="1" colspan="1">[-41,8; -24,9]</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Min/Maks</td>
                     <td rowspan="1" colspan="1">11,0/927,1</td>
                     <td rowspan="1" colspan="1">6,0/833,9</td>
                     <td rowspan="1" colspan="1">278,5/-767,3</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1">50,1/-82,7</td>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Vsota 3 največjih</td>
                     <td rowspan="1" colspan="1">191,7 (197,4)</td>
                     <td rowspan="1" colspan="1">123,5 (144,5)</td>
                     <td rowspan="1" colspan="1">-68,0 (145,5)</td>
                     <td rowspan="1" colspan="1">[-108,3; -27,7]</td>
                     <td rowspan="1" colspan="1">0,002</td>
                     <td rowspan="1" colspan="1">-32,3 (32,6)</td>
                     <td rowspan="1" colspan="1">[-41,3–23,3]</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Min/Maks</td>
                     <td rowspan="1" colspan="1">14,7/1074,6</td>
                     <td rowspan="1" colspan="1">10,3/518,4</td>
                     <td rowspan="1" colspan="1">282,2/-822,3</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1">47,2/-79,2</td>
                     <td rowspan="1" colspan="1"/>
                  </tr>
               </tbody>
            </table>
         </table-wrap>
         <p>Za več kot 10 % se je povprečna prostornina miomov zmanjšala pri 37 (74,0 %) preiskovankah. Pri teh bolnicah se je povprečna prostornina največjega mioma po končanem zdravljenju z UPA zmanjšala za 47,6 % (95 % IZ [-53,3; -41,9]), skupna povprečna prostornina do 3 največjih miomov pa za 48,5 % (95 % IZ [-54,0; -43,0]).</p>
         <p>Na prvi sliki je prikazana mediana sprememba vsote prostornin, prvi in tretji kvartil ter najnižja in najvišja vrednost v odstotkih do 3 največjih miomov.</p>
         <p>Pri vseh preiskovankah smo opazili porast koncentracije hemoglobina, povprečno za 24,3 g/l (od 5 do 76 g/l, SO 16,32 g/l, 95 % IZ [19,8; 28,8]), kar je bila statistično značilna razlika (p &lt; 0,001). Na <xref ref-type="fig" rid="fig2">Sliki 2</xref> je prikazan porast koncentracije Hb po končanem zdravljenju z UPA.</p>
         <fig position="anchor" id="fig2" orientation="portrait">
            <label>Slika 2:</label>
            <caption>
               <p> Mediani (1., 3. kvartil, min./maks.) porast koncentracije Hb po zdravljenju z UPA.</p>
            </caption>
            <p>
               <graphic xlink:href="2633-web-resources/image/zdravvestn-2633-sl-02.png"
                        position="float"
                        orientation="portrait"/>
            </p>
         </fig>
         <p>Neželene stranske učinke je imelo 11 (22,0 %) bolnic (<xref ref-type="table" rid="table3">Tabela 3</xref>). Nobena od bolnic s stranskimi učinki ni poiskala zdravniške pomoči ali prekinila zdravljenja z UPA. Štiri (8,0 %) bolnice so imele blage vročinske valove, 7 (14,0 %) blage do zmerne občasne glavobole, pri 3 (6,0 %) se je pojavila napetost dojk, 1 (2,0 %) bolnica je navajala zmanjšan tek in izpadanje las. Več kot en stranski učinek so imele 4 (8,0 %) bolnice. Po končanem zdravljenju z UPA smo z ultrazvočno preiskavo izmerili zadebeljen endometrij (&gt; 16 mm) pri 7 (14,0 %) preiskovankah. Pri 4, pri katerih smo napravili histerektomijo, je bila histološko potrjena PAEC, pri 3 pa smo odstranili le miome, tako da histološka preiskava endometrija ni bila opravljena.</p>
         <table-wrap position="anchor" id="table3" orientation="portrait">
            <label>Tabela 3:</label>
            <caption>
               <p> Neželeni stranski učinki pri posamezni bolnici.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Bolnica</th>
                     <th rowspan="1" colspan="1">Vročinski valovi</th>
                     <th rowspan="1" colspan="1">Glavobol</th>
                     <th rowspan="1" colspan="1">Napetost dojk</th>
                     <th rowspan="1" colspan="1">Zmanjšaje teka</th>
                     <th rowspan="1" colspan="1">Izpadanje las</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>1</p>
                     </td>
                     <td rowspan="1" colspan="1"/>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>2</p>
                     </td>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>3</p>
                     </td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>4</p>
                     </td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td align="center" rowspan="1" colspan="1">+</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>5</p>
                     </td>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>6</p>
                     </td>
                     <td rowspan="1" colspan="1"/>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>7</p>
                     </td>
                     <td rowspan="1" colspan="1"/>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>8</p>
                     </td>
                     <td rowspan="1" colspan="1"/>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>9</p>
                     </td>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>10</p>
                     </td>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>11</p>
                     </td>
                     <td rowspan="1" colspan="1"/>
                     <td align="center" rowspan="1" colspan="1">+</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
               </tbody>
            </table>
         </table-wrap>
         <p>Pri bolnicah, pri katerih smo izluščili miome, se je meja med miomi in miometrijem dobro ohranila. Opazili smo, da so miomi nekoliko mehkejši kot pri bolnicah, ki pred operacijo ne prejemajo UPA.</p>
      </sec>
      <sec id="s5" sec-type="Razpravljanje">
         <label>5</label>
         <title>Razpravljanje</title>
         <p>Medikamentno zdravljenje miomov je danes najpogosteje na mestu pred načrtovanim operacijskim posegom z namenom zmanjšati miome in izboljšati krvno sliko ter v raziskovalne namene (<xref ref-type="bibr" rid="b20">20</xref>,<xref ref-type="bibr" rid="b21">21</xref>). Naša raziskava je pokazala, da predoperacijsko zdravljenje z UPA učinkovito zmanjša velikost miomov pri večini bolnic in tako olajša ali celo omogoči endoskopsko operacijo. Čas operacije je pri manjših miomih nedvomno krajši, pomembno pa lahko velikost miomov vpliva tudi na izgubo krvi med operacijo (<xref ref-type="bibr" rid="b22">22</xref>,<xref ref-type="bibr" rid="b23">23</xref>). Kljub dejstvu, da ni šlo za randomizirano kontrolirano raziskavo, kar je nedvomno pomanjkljivost, so izsledki podobni izsledkom za skupine preiskovank, ki so prejemale enak odmerek UPA v randomiziranih kontroliranih raziskavah, ki jih je bilo do sedaj zelo malo in so delo ene same raziskovalne skupine.</p>
         <p>Prednost našega dela pa je tudi v vključitvi bolnic z miomi z večjim premerom od 100 mm in z drugimi simptomi miomov in ne zgolj bolnic s hipermenorejo in tistimi s premerom miomov, manjšim od 100 mm, kot so bile vključene v PEARL raziskave. V PEARL II in IV raziskavi so avtorji ugotovili, da predoperacijsko zdravljenje z UPA učinkovito zmanjša prostornino miomov. Skupna prostornina treh največjih miomov se je zmanjšala za 36 % oziroma 38 % (mediani) pri 97 oziroma 228 preiskovankah, ki so prejemale UPA v odmerku 5 mg. V naši raziskavi smo pri 50 preiskovankah ugotovili povprečno zmanjšanje skupne prostornine treh največjih miomov za 32,3 %, (95 % IZ [-41,3; -23,3]) (<xref ref-type="bibr" rid="b15">15</xref>,<xref ref-type="bibr" rid="b24">24</xref>).</p>
         <p>Pri bolnicah, pri katerih smo izluščili miome, nismo imeli težav, ker je bila meja med miomi in miometrijem dobro ohranjena. Opazili pa smo, da so miomi nekoliko mehkejši kot pri bolnicah, ki pred operacijo niso prejemale UPA. Ta subjektivna opažanja potrjujejo tudi drugi raziskovalci, ki so sodelovali v raziskavah, pri katerih so predoperacijsko zdravili bolnice z UPA (<xref ref-type="bibr" rid="b25">25</xref>). Po naših merilih uspešnosti zdravljenja, ki smo jih določili, če se je vsaj za 10 % zmanjšala prostornina miomov, je bilo zdravljenje neuspešno pri 26,0 % preiskovank. Z nedavno raziskavo smo ugotovili, da bi bilo zdravljenje z UPA pri mlajših bolnicah in/ali tistih z velikimi miomi lahko neuspešno (<xref ref-type="bibr" rid="b8">8</xref>).</p>
         <p>Po zdravljenju z UPA se je vsem preiskovankam zvečala koncentracija Hb, kar je bilo statistično značilno. Večina (82,0 %) jih je bila med zdravljenjem amenoroična, pri ostalih pa se je krvavitev pomembno zmanjšala in tako izboljšala oz. normalizirala krvna slika, kar je ugotovil tudi Donnez s sodelavci (<xref ref-type="bibr" rid="b15">15</xref>,<xref ref-type="bibr" rid="b19">19</xref>). Nedavna raziskava je pokazala, da imajo nekardiološke operacije pri slabokrvnih bolnikih slabše izide. Slabokrvnost, tudi manjše stopnje (hematokrit pri ženskah manjši kot 36 %), namreč pomembno vpliva na 30-dnevno pooperacijsko obolevnost in umrljivost pri bolnikih, ki so imeli večjo nekardiološko operacijo (<xref ref-type="bibr" rid="b26">26</xref>).</p>
         <p>UPA je zdravilo, ki je na voljo v obliki 5-miligramskih tablet. Zdravilo se jemlje enkrat dnevno 12 tednov in se prične jemati v prvem tednu menstruacijske krvavitve. Ta trimesečni cikel zdravljenja se lahko večkrat ponovi. Ponovno zdravljenje se začne med drugo menstruacijo, po zaključenem prejšnjem ciklu zdravljenja. Menstruacije se praviloma vrnejo v 4 tednih po koncu zdravljenja (<xref ref-type="bibr" rid="b27">27</xref>). Najpogostejši stranski učinek UPA je amenoreja, ki pa je celo zaželena. Pogosti neželeni učinki so tudi glavobol, utrujenost, slabost, bolečina v trebuhu, vrtoglavica, akne, bolečine v mišicah in skeletu, vročinski valovi, ciste na jajčnikih in občutljivost dojk. Uporaba ni priporočljiva pri bolnicah s hudo ledvično okvaro, z zmerno ali hudo jetrno okvaro in pri bolnicah, mlajših od 18 let. Uporaba je kontraindicirana pri preobčutljivosti na zdravilno učinkovino ali katero koli pomožno snov, pri ženskah, ki so noseče ali dojijo, krvavijo iz spolovil iz neznanega razloga ali razloga, ki ni povezan z miomi maternice, in pri bolnicah z rakom materničnega vratu, jajčnikov ali dojk (<xref ref-type="bibr" rid="b28">28</xref>). Odbor za oceno tveganja na področju farmakovigilance (Pharmacovigilance Risk Assessment Committee, PRAC) pri Evropski agenciji za zdravila je v dokumentu EMA/355940/2018 izdal priporočila, ki jih je 1. 6. 2018 sprejel Odbor za zdravila za uporabo v humani medicini (Committee for Medicinal Products for Human Use, CHMP) o ukrepih za zmanjšanje tveganja za zaplete zaradi morebitne hepatotoksičnosti UPA. Pred pričetkom zdravljenja z UPA je treba vsem bolnicam opraviti funkcionalne jetrne preiskave. Če so jetrni encimi več kot 2-krat višji od zgornje normalne vrednosti, se zdravila ne sme predpisati. Funkcionalne jetrne preiskave je treba ponoviti vsak mesec jemanja zdravila in nato še 2–4 tedne po končanem zdravljenju. Če so vrednosti jetrnih encimov 3-krat nad zgornjo normalno vrednostjo, je treba zdravljenje prekiniti in bolnico skrbno nadzorovati. Več ciklusov UPA naj se predpiše le bolnicam, ki niso primerne za operacijsko zdravljenje. Pred načrtovano operacijo naj se predpiše le en ciklus UPA (<xref ref-type="bibr" rid="b29">29</xref>).</p>
         <p>V naši raziskavi smo pri večini bolnic v kratkem času dosegli amenorejo ali znatno zmanjšanje krvavitve iz maternice, kar je bil želeni učinek. Približno petina bolnic je navajala blage neželene stranske učinke, najpogosteje glavobol, kar je primerljivo z drugimi raziskavami (<xref ref-type="bibr" rid="b12">12</xref>,<xref ref-type="bibr" rid="b15">15</xref>,<xref ref-type="bibr" rid="b19">19</xref>,<xref ref-type="bibr" rid="b24">24</xref>).</p>
         <p>Uporaba UPA je bila raziskana v kliničnih raziskavah PEARL I PEARL II, PEARL III, PEARL III extension in PEARL IV. Raziskovalci so v PEARL I primerjali uporabo UPA in placeba pri bolnicah s simptomi, ki so bile predvidene za operacijsko zdravljenje. Vsem so dali pripravke železa in UPA v odmerku 5 mg (96 preiskovank) ali 10 mg na dan (98 preiskovank) ali placebo (48 preiskovank) za 12 tednov. Opazovali so količino krvavitve iz maternice, krvno sliko pred začetkom in po zaključku zdravljenja ter velikost miomov. Ugotovili so, da je zdravljenje z UPA v obeh odmerkih učinkovito obvladovalo krvavitev iz maternice (večina bolnic je bila amenoroičnih po 10 dneh uporabe UPA) izboljšalo krvno sliko in zmanjšalo mediano prostornino miomov za 21 % (<xref ref-type="bibr" rid="b19">19</xref>).</p>
         <p>V raziskavi PEARL II so primerjali učinkovitost odmerkov UPA 5 (97 preiskovank) ali 10 mg (103 preiskovanke) in GnRHa leuprolid acetata (101 preiskovanka) v predoperacijskem zdravljenju miomov, ki so povzročali simptome. Ugotovili so, da razlika med skupinama preiskovank, ki so prejemale 5 oz. 10 mg UPA na dan, ni bila statistično značilna v primerjavi z mesečnimi injekcijami leuprolid acetata glede zmanjševanja krvavitev iz maternice zaradi miomov. Krvavitev se je zmanjšala pri 90,0 % bolnic, ki so prejemale 5 mg UPA, pri 98,0 % bolnic, ki so prejemale 10 mg UPA in pri 89 % bolnic, ki so prejemale leuprolid acetat. Bolnice, ki so prejemale UPA, so imele tudi značilno manj vročinskih valov (10,0 % oz. 11,0 % v skupinah z UPA in 40,0 % v skupini z leuprolid acetatom). Preliminarni rezultati so pokazali tudi daljši učinek zmanjšanja prostornine miomov pri bolnicah, ki niso bile operirane. V skupini z leuprolid acetatom so se miomi začeli ponovno večati že mesec dni po zadnjem odmerku, medtem ko v skupini z UPA pri večini bolnic po 6 mesecih niso opazili povečanja miomov (<xref ref-type="bibr" rid="b15">15</xref>).</p>
         <p>V raziskavi PEARL III (209 preiskovank) in PEARL III extension (132 preiskovank) so raziskovali učinkovitost in varnost dolgotrajnejše uporabe UPA za zdravljenje bolnic z miomi, ki so povzročali simptome. Jemanje UPA z vmesnimi prekinitvami 4 cikle je povzročilo amenorejo pri večini bolnic in nadaljnje zmanjšanje miomov. Ti podatki kažejo, da UPA lahko povzroči apoptozo in zmanjša proliferacijo miomskih celic, kar bi lahko vodilo v regresijo bolezni (<xref ref-type="bibr" rid="b12">12</xref>,<xref ref-type="bibr" rid="b14">14</xref>,<xref ref-type="bibr" rid="b19">19</xref>).</p>
         <p>Tudi v raziskavi PEARL IV so, podobno kot v prejšnjih dveh raziskavah, avtorji preverjali učinkovitost in varnost dolgotrajne uporabe UPA pri bolnicah z miomi, ki so povzročali simptome. Preiskovanke so prejemale 5 mg (228 preiskovank) ali 10 mg (223 preiskovank) UPA po 12 tednov z vmesnimi prekinitvami, tako da so preiskovanke pričele ponovno jemati UPA med drugo menstruacijo po končanem ciklu jemanja zdravila pred tem. V obeh skupinah je bila večina preiskovank med jemanjem UPA amenoroičnih (69,6 % in 74,5 %). Razlika med skupinama s 5 oziroma 10 mg UPA ni bila statistično značilna. V obeh skupinah preiskovank se je prostornina miomov za 25 % ali več zmanjšala pri 78,0 % oziroma 80,1 % preiskovank, kar tudi ni bila statistično značilna razlika. S to raziskavo so avtorji še dodatno potrdili učinkovitost in varnost dolgotrajnega zdravljenja z UPA (<xref ref-type="bibr" rid="b13">13</xref>,<xref ref-type="bibr" rid="b24">24</xref>).</p>
         <p>V raziskavi, ki je spremljala bolnice, ki so sodelovale v raziskavi PEARL II in PEARL III in so kasneje želele zanositi, je bilo opisanih prvih nekaj uspešnih nosečnosti. Kar 21 bolnic po predoperacijskem zdravljenju z UPA je želelo zanositi, 15 bolnicam (71,0 %) je to tudi uspelo. Rodilo se je 13 zdravih otrok (12 porodov), 6 žensk je imelo splav v zgodnji nosečnosti. Pri dveh bolnicah, ki sta zanosili, so miomi skoraj popolnoma izginili, tako da operacijsko zdravljenje ni bilo potrebno. V raziskavi tudi niso opazili ponovne rasti miomov v nosečnosti, kar kaže na dolgotrajnejši učinek zmanjšanja miomov (<xref ref-type="bibr" rid="b30">30</xref>). Opisanih je že tudi nekaj primerov uspešnih nosečnosti po zdravljenju miomov, ki so povzročali simptome, z UPA brez potrebe po kasnejši operaciji (<xref ref-type="bibr" rid="b31">31</xref>,<xref ref-type="bibr" rid="b32">32</xref>).</p>
      </sec>
      <sec id="s6" sec-type="Zaključek">
         <label>6</label>
         <title>Zaključek</title>
         <p>Z našo raziskavo smo ugotovili, da predoperacijsko zdravljenje z UPA učinkovito zmanjša velikost miomov in izboljša krvno sliko, kar olajša oziroma omogoči najsodobnejše načine endoskopskega operiranja in zmanjšuje tveganje za zaplete po operaciji. Kljub pomanjkljivosti raziskave, ki ni bila randomizirano kontrolirana, so rezultati podobni do sedaj še maloštevilnim randomizirno kontroliranim raziskavam. V naši, kot tudi drugih raziskavah, so preiskovanke UPA dobro prenašala in imele sorazmerno malo stranskih učinkov. Kljub temu bo treba opraviti še veliko raziskav o učinkovitosti in predvsem varnosti UPA, saj se je v zadnjih mesecih pojavil sum o možni hepatotoksičnosti zdravila.</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="b1">
            <label>1. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Marshall</surname>
                     <given-names>LM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Spiegelman</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Barbieri</surname>
                     <given-names>RL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goldman</surname>
                     <given-names>MB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Manson</surname>
                     <given-names>JE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Colditz</surname>
                     <given-names>GA</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Variation in the incidence of uterine leiomyoma among premenopausal women by age and race</article-title>. 
                    <source>Obstet Gynecol</source>. 
                    <year>1997</year>
                    <month>Dec</month>;
                    <volume>90</volume>(
                    <issue>6</issue>):
                    <fpage>967</fpage>–
                    <lpage>73</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0029-7844(97)00534-6</pub-id>
                    <pub-id pub-id-type="pmid">9397113</pub-id>
                    <issn>0029-7844</issn>
                </mixed-citation>
         </ref>
         <ref id="b2">
            <label>2. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sabry</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Al-Hendy</surname>
                     <given-names>A</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Medical treatment of uterine leiomyoma</article-title>. 
                    <source>Reprod Sci</source>. 
                    <year>2012</year>
                    <month>Apr</month>;
                    <volume>19</volume>(
                    <issue>4</issue>):
                    <fpage>339</fpage>–
                    <lpage>53</lpage>. 
                    <pub-id pub-id-type="doi">10.1177/1933719111432867</pub-id>
                    <pub-id pub-id-type="pmid">22378865</pub-id>
                    <issn>1933-7191</issn>
                </mixed-citation>
         </ref>
         <ref id="b3">
            <label>3. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Parker</surname>
                     <given-names>WH</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Uterine myomas: management</article-title>. 
                    <source>Fertil Steril</source>. 
                    <year>2007</year>
                    <month>Aug</month>;
                    <volume>88</volume>(
                    <issue>2</issue>):
                    <fpage>255</fpage>–
                    <lpage>71</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.fertnstert.2007.06.044</pub-id>
                    <pub-id pub-id-type="pmid">17658523</pub-id>
                    <issn>0015-0282</issn>
                </mixed-citation>
         </ref>
         <ref id="b4">
            <label>4. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Talaulikar</surname>
                     <given-names>VS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Manyonda</surname>
                     <given-names>I</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids</article-title>. 
                    <source>Eur J Obstet Gynecol Reprod Biol</source>. 
                    <year>2012</year>
                    <month>Dec</month>;
                    <volume>165</volume>(
                    <issue>2</issue>):
                    <fpage>135</fpage>–
                    <lpage>40</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ejogrb.2012.07.023</pub-id>
                    <pub-id pub-id-type="pmid">22901974</pub-id>
                    <issn>0301-2115</issn>
                </mixed-citation>
         </ref>
         <ref id="b5">
            <label>5. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sankaran</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Manyonda</surname>
                     <given-names>IT</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Medical management of fibroids</article-title>. 
                    <source>Best Pract Res Clin Obstet Gynaecol</source>. 
                    <year>2008</year>
                    <month>Aug</month>;
                    <volume>22</volume>(
                    <issue>4</issue>):
                    <fpage>655</fpage>–
                    <lpage>76</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.bpobgyn.2008.03.001</pub-id>
                    <pub-id pub-id-type="pmid">18468953</pub-id>
                    <issn>1521-6934</issn>
                </mixed-citation>
         </ref>
         <ref id="b6">
            <label>6. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Trefoux Bourdet</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Luton</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Koskas</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence</article-title>. 
                    <source>Int J Womens Health</source>. 
                    <year>2015</year>
                    <month>Mar</month>;
                    <volume>7</volume>:
                    <fpage>321</fpage>–
                    <lpage>30</lpage>.
                    <pub-id pub-id-type="doi">10.2147/IJWH.S50016</pub-id>
                    <pub-id pub-id-type="pmid">25848323</pub-id>
                    <issn>1179-1411</issn>
                </mixed-citation>
         </ref>
         <ref id="b7">
            <label>7. </label>
            <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ribič-Pucelj</surname>
                     <given-names>M</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>Tomaževič</surname>
                     <given-names>T</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>Vogler</surname>
                     <given-names>A</given-names>
                  </name>
                    </person-group>.  
                    <chapter-title>Laparoskopska miomektomija</chapter-title>. In:
                    <person-group person-group-type="editor">
                        <name name-style="western">
                     <surname>Ribič-Pucelj</surname>
                     <given-names>M</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>Pegan</surname>
                     <given-names>V</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>Pašić</surname>
                     <given-names>RP</given-names>
                  </name>
                    </person-group>.
                    <source>Endoskopske operacije v ginekologiji</source>.
                    <publisher-loc>Radovljica</publisher-loc>:
                    <publisher-name>Didakta</publisher-name>;
                    <year>2007</year>. pp. 
                    <fpage>207</fpage>–
                    <lpage>15</lpage>.
                </mixed-citation>
         </ref>
         <ref id="b8">
            <label>8. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Brun</surname>
                     <given-names>JL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rajaonarison</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Froeliger</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Monseau-Thiburce</surname>
                     <given-names>AC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Randriamboavonjy</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vogler</surname>
                     <given-names>A</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy</article-title>. 
                    <source>Eur J Obstet Gynecol Reprod Biol</source>. 
                    <year>2018</year>
                    <month>Mar</month>;
                    <volume>222</volume>:
                    <fpage>13</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ejogrb.2017.12.033</pub-id>
                    <pub-id pub-id-type="pmid">29328939</pub-id>
                    <issn>0301-2115</issn>
                </mixed-citation>
         </ref>
         <ref id="b9">
            <label>9. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sinai Talaulikar</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Belli</surname>
                     <given-names>AM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Manyonda</surname>
                     <given-names>I</given-names>
                  </name>
                    </person-group>. 
                    <article-title>GnRH agonists: do they have a place in the modern management of fibroid disease?</article-title>
                    <source>J Obstet Gynaecol India</source>. 
                    <year>2012</year>
                    <month>Oct</month>;
                    <volume>62</volume>(
                    <issue>5</issue>):
                    <fpage>506</fpage>–
                    <lpage>10</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s13224-012-0206-0</pub-id>
                    <pub-id pub-id-type="pmid">24082548</pub-id>
                    <issn>0022-3190</issn>
                </mixed-citation>
         </ref>
         <ref id="b10">
            <label>10. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lethaby</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vollenhoven</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sowter</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review</article-title>. 
                    <source>BJOG</source>. 
                    <year>2002</year>
                    <month>Oct</month>;
                    <volume>109</volume>(
                    <issue>10</issue>):
                    <fpage>1097</fpage>–
                    <lpage>108</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1471-0528.2002.01225.x</pub-id>
                    <pub-id pub-id-type="pmid">12387461</pub-id>
                    <issn>1470-0328</issn>
                </mixed-citation>
         </ref>
         <ref id="b11">
            <label>11. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Mavrelos</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ben-Nagi</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Davies</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lee</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Salim</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jurkovic</surname>
                     <given-names>D</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo-controlled randomized trial</article-title>. 
                    <source>Hum Reprod</source>. 
                    <year>2010</year>
                    <month>Sep</month>;
                    <volume>25</volume>(
                    <issue>9</issue>):
                    <fpage>2264</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/humrep/deq188</pub-id>
                    <pub-id pub-id-type="pmid">20663795</pub-id>
                    <issn>0268-1161</issn>
                </mixed-citation>
         </ref>
         <ref id="b12">
            <label>12. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Donnez</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vázquez</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tomaszewski</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nouri</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bouchard</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fauser</surname>
                     <given-names>BC</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>PEARL III and PEARL III Extension Study Group</collab>
                    </person-group>. 
                    <article-title>Long-term treatment of uterine fibroids with ulipristal acetate</article-title>. 
                    <source>Fertil Steril</source>. 
                    <year>2014</year>
                    <month>Jun</month>;
                    <volume>101</volume>(
                    <issue>6</issue>):
                    <fpage>1565</fpage>–
                    <lpage>73.e1</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.fertnstert.2014.02.008</pub-id>
                    <pub-id pub-id-type="pmid">24630081</pub-id>
                    <issn>0015-0282</issn>
                </mixed-citation>
         </ref>
         <ref id="b13">
            <label>13. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Donnez</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Donnez</surname>
                     <given-names>O</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matule</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ahrendt</surname>
                     <given-names>HJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hudecek</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zatik</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Long-term medical management of uterine fibroids with ulipristal acetate</article-title>. 
                    <source>Fertil Steril</source>. 
                    <year>2016</year>
                    <month>Jan</month>;
                    <volume>105</volume>(
                    <issue>1</issue>):
                    <fpage>165</fpage>–
                    <lpage>173.e4</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.fertnstert.2015.09.032</pub-id>
                    <pub-id pub-id-type="pmid">26477496</pub-id>
                    <issn>0015-0282</issn>
                </mixed-citation>
         </ref>
         <ref id="b14">
            <label>14. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Powell</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dutta</surname>
                     <given-names>D</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Esmya
                        <sup>®</sup> and the PEARL studies: A review
                    </article-title>. 
                    <source>Womens Health (Lond)</source>. 
                    <year>2016</year>
                    <month>Nov</month>;
                    <volume>12</volume>(
                    <issue>6</issue>):
                    <fpage>544</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1177/1745505717692591</pub-id>
                    <pub-id pub-id-type="pmid">29334010</pub-id>
                    <issn>1745-5065</issn>
                </mixed-citation>
         </ref>
         <ref id="b15">
            <label>15. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Donnez</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tomaszewski</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vázquez</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bouchard</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lemieszczuk</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Baró</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>PEARL II Study Group</collab>
                    </person-group>. 
                    <article-title>Ulipristal acetate versus leuprolide acetate for uterine fibroids</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2012</year>
                    <month>Feb</month>;
                    <volume>366</volume>(
                    <issue>5</issue>):
                    <fpage>421</fpage>–
                    <lpage>32</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1103180</pub-id>
                    <pub-id pub-id-type="pmid">22296076</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
         </ref>
         <ref id="b16">
            <label>16. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Biglia</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Carinelli</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Maiorana</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>D’Alonzo</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lo Monte</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Marci</surname>
                     <given-names>R</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids</article-title>. 
                    <source>Drug Des Devel Ther</source>. 
                    <year>2014</year>
                    <month>Feb</month>;
                    <volume>8</volume>:
                    <fpage>285</fpage>–
                    <lpage>92</lpage>.
                    <pub-id pub-id-type="doi">10.2147/DDDT.S54565</pub-id>
                    <pub-id pub-id-type="pmid">24591818</pub-id>
                    <issn>1177-8881</issn>
                </mixed-citation>
         </ref>
         <ref id="b17">
            <label>17. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Fiscella</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bonfiglio</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Winters</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Eisinger</surname>
                     <given-names>SH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fiscella</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone</article-title>. 
                    <source>Hum Pathol</source>. 
                    <year>2011</year>
                    <month>Jul</month>;
                    <volume>42</volume>(
                    <issue>7</issue>):
                    <fpage>947</fpage>–
                    <lpage>53</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.humpath.2010.11.003</pub-id>
                    <pub-id pub-id-type="pmid">21315422</pub-id>
                    <issn>0046-8177</issn>
                </mixed-citation>
         </ref>
         <ref id="b18">
            <label>18. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Williams</surname>
                     <given-names>AR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bergeron</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Barlow</surname>
                     <given-names>DH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ferenczy</surname>
                     <given-names>A</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate</article-title>. 
                    <source>Int J Gynecol Pathol</source>. 
                    <year>2012</year>
                    <month>Nov</month>;
                    <volume>31</volume>(
                    <issue>6</issue>):
                    <fpage>556</fpage>–
                    <lpage>69</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/PGP.0b013e318251035b</pub-id>
                    <pub-id pub-id-type="pmid">23018219</pub-id>
                    <issn>0277-1691</issn>
                </mixed-citation>
         </ref>
         <ref id="b19">
            <label>19. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Donnez</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tatarchuk</surname>
                     <given-names>TF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bouchard</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Puscasiu</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zakharenko</surname>
                     <given-names>NF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ivanova</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>PEARL I Study Group</collab>
                    </person-group>. 
                    <article-title>Ulipristal acetate versus placebo for fibroid treatment before surgery</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2012</year>
                    <month>Feb</month>;
                    <volume>366</volume>(
                    <issue>5</issue>):
                    <fpage>409</fpage>–
                    <lpage>20</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1103182</pub-id>
                    <pub-id pub-id-type="pmid">22296075</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
         </ref>
         <ref id="b20">
            <label>20. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sabry</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Al-Hendy</surname>
                     <given-names>A</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Innovative oral treatments of uterine leiomyoma</article-title>. 
                    <source>Obstet Gynecol Int</source>. 
                    <year>2012</year>;
                    <volume>2012</volume>:
                    <fpage>943635</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2012/943635</pub-id>
                    <pub-id pub-id-type="pmid">22518167</pub-id>
                    <issn>1687-9589</issn>
                </mixed-citation>
         </ref>
         <ref id="b21">
            <label>21. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Duhan</surname>
                     <given-names>N</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Current and emerging treatments for uterine myoma - an update</article-title>. 
                    <source>Int J Womens Health</source>. 
                    <year>2011</year>;
                    <volume>3</volume>(
                    <issue>1</issue>):
                    <fpage>231</fpage>–
                    <lpage>41</lpage>. 
                    <pub-id pub-id-type="doi">10.2147/IJWH.S15710</pub-id>
                    <pub-id pub-id-type="pmid">21892334</pub-id>
                    <issn>1179-1411</issn>
                </mixed-citation>
         </ref>
         <ref id="b22">
            <label>22. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ginsburg</surname>
                     <given-names>ES</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Benson</surname>
                     <given-names>CB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Garfield</surname>
                     <given-names>JM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gleason</surname>
                     <given-names>RE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Friedman</surname>
                     <given-names>AJ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The effect of operative technique and uterine size on blood loss during myomectomy: a prospective randomized study</article-title>. 
                    <source>Fertil Steril</source>. 
                    <year>1993</year>
                    <month>Dec</month>;
                    <volume>60</volume>(
                    <issue>6</issue>):
                    <fpage>956</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0015-0282(16)56392-4</pub-id>
                    <pub-id pub-id-type="pmid">8243699</pub-id>
                    <issn>0015-0282</issn>
                </mixed-citation>
         </ref>
         <ref id="b23">
            <label>23. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Leone Roberti Maggiore</surname>
                     <given-names>U</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Scala</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Venturini</surname>
                     <given-names>PL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ferrero</surname>
                     <given-names>S</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Preoperative treatment with letrozole in patients undergoing laparoscopic myomectomy of large uterine myomas: a prospective non-randomized study</article-title>. 
                    <source>Eur J Obstet Gynecol Reprod Biol</source>. 
                    <year>2014</year>
                    <month>Oct</month>;
                    <volume>181</volume>:
                    <fpage>157</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ejogrb.2014.07.040</pub-id>
                    <pub-id pub-id-type="pmid">25150954</pub-id>
                    <issn>0301-2115</issn>
                </mixed-citation>
         </ref>
         <ref id="b24">
            <label>24. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Donnez</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hudecek</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Donnez</surname>
                     <given-names>O</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matule</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Arhendt</surname>
                     <given-names>HJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zatik</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids</article-title>. 
                    <source>Fertil Steril</source>. 
                    <year>2015</year>
                    <month>Feb</month>;
                    <volume>103</volume>(
                    <issue>2</issue>):
                    <fpage>519</fpage>–
                    <lpage>27.e3</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.fertnstert.2014.10.038</pub-id>
                    <pub-id pub-id-type="pmid">25542821</pub-id>
                    <issn>0015-0282</issn>
                </mixed-citation>
         </ref>
         <ref id="b25">
            <label>25. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Rabe</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ahrendt</surname>
                     <given-names>HJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Albring</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bitzer</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bouchard</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cirkel</surname>
                     <given-names>U</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Ulipristal acetate for symptomatic uterine fibroids and myoma-related hypermenorrhea: joint statement by the german society for gynecological endocrinology and reproductive medicine (DGGEF) and the german professional association of gynecologist (BVF)</article-title>. 
                    <source>J Reproduktionsmed Endokrinol</source>.
                    <year>2013</year>;
                    <volume>10</volume>(
                    <issue>Special Issue 1</issue>):
                    <fpage>82</fpage>–
                    <lpage>101</lpage>.
                </mixed-citation>
         </ref>
         <ref id="b26">
            <label>26. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Musallam</surname>
                     <given-names>KM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tamim</surname>
                     <given-names>HM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Richards</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Spahn</surname>
                     <given-names>DR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rosendaal</surname>
                     <given-names>FR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Habbal</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study</article-title>. 
                    <source>Lancet</source>. 
                    <year>2011</year>
                    <month>Oct</month>;
                    <volume>378</volume>(
                    <issue>9800</issue>):
                    <fpage>1396</fpage>–
                    <lpage>407</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0140-6736(11)61381-0</pub-id>
                    <pub-id pub-id-type="pmid">21982521</pub-id>
                    <issn>0140-6736</issn>
                </mixed-citation>
         </ref>
         <ref id="b27">
            <label>27. </label>
            <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <collab>European medicines agency. Science medicines health</collab>.
                    </person-group>.
                    <source>Esmya (ulipristalacetat)</source>. 
                    <comment>Available from:<uri>http://www.ema.europa.eu/docs/sl_SI/document_library/EPAR_-_Summary_for_the_public/human/002041/WC500124089.pdf</uri>
               </comment>. 
                </mixed-citation>
         </ref>
         <ref id="b28">
            <label>28. </label>
            <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <collab>European medicines agency. Science medicines health</collab>.
                    </person-group>.
                    <source>Priloga 1. Povzetek glavnih značilnosti zdravila</source>. 
                    <comment>Available from:<uri>http://www.ema.europa.eu/docs/sl_SI/document_library/EPAR_-_Product_Information/human/002041/WC500124085.pdf</uri>
               </comment>. 
           </mixed-citation>
         </ref>
         <ref id="b29">
            <label>29. </label>
            <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <collab>European medicines agency. Science medicines health</collab>.
                    </person-group>.
                    <source>PAssessment report on provisional measures </source>. 
                    <comment>Available from:<uri>https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-assessment-report-provisional-measures_en.pdf</uri>
               </comment>. 
                </mixed-citation>
         </ref>
         <ref id="b30">
            <label>30. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Luyckx</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Squifflet</surname>
                     <given-names>JL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jadoul</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Votino</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dolmans</surname>
                     <given-names>MM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Donnez</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids</article-title>. 
                    <source>Fertil Steril</source>. 
                    <year>2014</year>
                    <month>Nov</month>;
                    <volume>102</volume>(
                    <issue>5</issue>):
                    <fpage>1404</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.fertnstert.2014.07.1253</pub-id>
                    <pub-id pub-id-type="pmid">25241376</pub-id>
                    <issn>0015-0282</issn>
                </mixed-citation>
         </ref>
         <ref id="b31">
            <label>31. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Monleón</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Martínez-Varea</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Galliano</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pellicer</surname>
                     <given-names>A</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Successful pregnancy after treatment with ulipristal acetate for uterine fibroids</article-title>. 
                    <source>Case Rep Obstet Gynecol</source>. 
                    <year>2014</year>;
                    <volume>2014</volume>:
                    <fpage>314587</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2014/314587</pub-id>
                    <pub-id pub-id-type="pmid">25143845</pub-id>
                    <issn>2090-6684</issn>
                </mixed-citation>
         </ref>
         <ref id="b32">
            <label>32. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Murad</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Spontaneous pregnancy following ulipristal acetate treatment in a woman with a symptomatic uterine fibroid</article-title>. 
                    <source>J Obstet Gynaecol Can</source>. 
                    <year>2016</year>
                    <month>Jan</month>;
                    <volume>38</volume>(
                    <issue>1</issue>):
                    <fpage>75</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jogc.2015.11.004</pub-id>
                    <pub-id pub-id-type="pmid">26872760</pub-id>
                    <issn>1701-2163</issn>
                </mixed-citation>
         </ref>
      </ref-list>
   </back>
   <sub-article id="article-en" xml:lang="en" article-type="other">
      <front-stub>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Human reproduction</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Original scientific article</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="en">
               <subject>Human reproduction</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="en">Preoperative treatment of uterine leiomyomas with ulipristal acetate</article-title>
            <alt-title alt-title-type="running-head" xml:lang="en">Preoperative treatment of uterine leiomyomas with ulipristal acetate</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Vogler</surname>
                  <given-names>Andrej</given-names>
               </name>
               <xref ref-type="aff" rid="en-aff1">1</xref>
               <xref ref-type="corresp" rid="en-corr"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Rajić</surname>
                  <given-names>Mišo</given-names>
               </name>
               <xref ref-type="aff" rid="en-aff1">1</xref>
            </contrib>
         </contrib-group>
         <aff id="en-aff1" xml:lang="en">
            <label>1</label>
            <institution>Department of Human Reproduction, Division of Gynaecology, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
         </aff>
         <abstract xml:lang="en">
            <title>Abstract</title>
            <p>Background: Uterine leiomyomas are the most common benign uterine tumours in women. They are symptomatic in 20 to 50 % of cases. Symptoms associated with leiomyomas include heavy, prolonged menstrual bleeding leading to anaemia, dysmenorrhoea, pelvic pressure and pain, impaired function of adjacent organs, such as bladder and bowel, and reproduction dysfunction. Options for medical therapy are currently limited to preoperative reduction of symptoms related to uterine bleeding and fibroid size. Recently, selective progesterone receptor modulators (SPRM) have been introduced and approved in preoperative treatment of leiomyomas. The aim of our study was to assess the efficacy of preoperative treatment with SPRM ulipristal acetate (UPA) on leiomyoma shrinkage and haemoglobin (Hb) concentration improvement.</p>
            <p>Methods: Fifty patients with symptomatic leiomyomas were assigned for preoperative treatment with 5 mg of UPA daily for 12 weeks. Before and a week after the UPA treatment was completed, leiomyoma volume was measured, and Hb concentrations and the amount of uterine bleeding were assessed. The outcomes were changes from baseline in leiomyoma volume and the proportion of patients with controlled bleeding after the treatment.</p>
            <p>Results: After the completion of UPA treatment there was a mean volume reduction of the largest myoma by 33.3 %, whereas the mean volume reduction of up to 3 largest myomas was 32.3 %. Volume reduction was in both cases statistically significant. During the treatment course 41 (82.0 %) women were amenorrhoeic and the other 9 (18.0 %) had a significant reduction in uterine bleeding. The reduction in bleeding was accompanied by improvement in Hb levels in all patients.</p>
            <p>Conclusion: Preoperative treatment with UPA for 12 weeks effectively reduces leiomyoma volume and facilitates or even makes laparoscopic surgery feasible. It is also beneficial for correcting anaemia, which is of outmost importance for postoperative recovery.</p>
         </abstract>
      </front-stub>
      <body>
         <sec id="en-s1" sec-type="Introduction">
            <label>1</label>
            <title>Introduction</title>
            <p>Leiomyomas are the most common benign uterine tumours, being encountered in 30–70 % of women in fertile period (<xref ref-type="bibr" rid="en-b1">1</xref>). Fibroids are monoclonal tumours of the smooth muscle of the endometrium; they contain large quantities of collagen-, fibronectin- and proteoglycan-containing extracellular matrix (<xref ref-type="bibr" rid="en-b2">2</xref>). Approximately a fifth to a half of women with leiomyomas present with symptoms that adversely affect their health or quality of life. Most frequently the complaints include prolonged and/or excessive menstrual bleedings that cause anaemia, dysmenorrhoea, pains due to pressure exerted on adjacent organs, and less frequently infertility and bladder and bowel dysfunction. The very origin of leiomyomas has not yet been fully explained, but it is well known that these tumours are hormone-dependent. Fibroid growth is mainly influenced by ovarian steroid hormones estrogens and progesterone as well as by local growth factors (<xref ref-type="bibr" rid="en-b3">3</xref>,<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
            <fig position="anchor" id="en-fig1" orientation="portrait">
               <label>Figure 1:</label>
               <caption>
                  <p> Median (1<sup>st</sup> and 3<sup>rd</sup> quartile, min./max.) change in the sum of volumes of up to 3 largest myomas.</p>
               </caption>
               <p>
                  <graphic xlink:href="2633-en-web-resources/image/zdravvestn-2633-en-01.png"
                           position="float"
                           orientation="portrait"/>
               </p>
            </fig>
            <p>Treatment is required in patients with symptoms and in cases of rapidly growing myomas. In pregnancy-planning women with asymptomatic myomas, these must be removed only if they cause deformities of the uterine cavity. Unfortunately, there has been no medicine yet that could completely remove myomas, and neither is it expected to be available in the near future (<xref ref-type="bibr" rid="en-b5">5</xref>,<xref ref-type="bibr" rid="en-b6">6</xref>). Therefore, despite certain non-surgical options for myoma treatment, such as embolisation of the uterine artery and MRI-guided focused sonography, hysterectomy or myomectomy still remain the most common treatment modalities. Most patients can be operated laparoscopically or hysteroscopically, however, such a treatment approach has limitations in terms of the number and size of myomas or the uterus itself (<xref ref-type="bibr" rid="en-b7">7</xref>). Medication treatment is generally limited to the alleviation of symptoms prior to surgery, in particular of heavy bleedings and anaemia, as well as to the reduction of myoma size (<xref ref-type="bibr" rid="en-b8">8</xref>). Presently, the only substances registered for medical treatment of leiomyomas are gonadoliberin agonists (GnRHa) and ulipristal acetate (UPA), a selective progesterone receptor modulator, which has been registered in Europe since 2012. GnRHa induce a transient menopause. Due to a decrease in oestrogen and progesterone levels, the uterus and myomas are temporarily reduced and (menstrual) bleedings discontinued, which can be beneficial before the planned surgical intervention. GnRHa have several adverse effects due to the induced hypo-oestrogen state, including the loss of bone density, which renders them unsuitable for prolonged use. They are also less suitable for myoma reduction prior to myomectomy, as the cleavage plane between the normal myometrium and myoma is obscured (<xref ref-type="bibr" rid="en-b9">9</xref>,<xref ref-type="bibr" rid="en-b10">10</xref>,<xref ref-type="bibr" rid="en-b11">11</xref>).</p>
            <p>Presently, SMPR seem to be the most promising medications for preoperative treatment of leiomyomas. The latest SMPR studies also indicate the safety of ulipristal acetate (UPA) for long-term use. Such long-term treatment could help to avoid the need of surgery particularly in premenopausal women (<xref ref-type="bibr" rid="en-b12">12</xref>,<xref ref-type="bibr" rid="en-b13">13</xref>,<xref ref-type="bibr" rid="en-b14">14</xref>). UPA triggers the apoptosis of myoma cells, thus reducing myoma volume by up to 46 %, and by inhibiting ovulation induces amenorrhoea in up to 90 % of patients (<xref ref-type="bibr" rid="en-b12">12</xref>,<xref ref-type="bibr" rid="en-b15">15</xref>). UPA does not affect the baseline values of gonadotropic hormones and therefore does not cause hypo-estrogenism (<xref ref-type="bibr" rid="en-b16">16</xref>). SMPR treatment may cause a benign, nonphysiological, non-proliferative histological change of the endometrium, the so-called progesterone receptor modulator associated endometrial changes (PAEC) (<xref ref-type="bibr" rid="en-b17">17</xref>,<xref ref-type="bibr" rid="en-b18">18</xref>). This change vanishes spontaneously within a few weeks to months after discontinuation of UPA treatment (<xref ref-type="bibr" rid="en-b12">12</xref>,<xref ref-type="bibr" rid="en-b15">15</xref>,<xref ref-type="bibr" rid="en-b19">19</xref>).</p>
            <table-wrap position="anchor" id="en-table1" orientation="portrait">
               <label>Table 1:</label>
               <caption>
                  <p> Indications for surgery</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Indications</th>
                        <th align="right" rowspan="1" colspan="1">No. of patients</th>
                        <th align="right" rowspan="1" colspan="1">%</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Hypermenorrhoea</td>
                        <td align="right" rowspan="1" colspan="1">17</td>
                        <td align="right" rowspan="1" colspan="1">34.0</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Hypermenorrhoea and dysmenorrhoea</td>
                        <td align="right" rowspan="1" colspan="1">14</td>
                        <td align="right" rowspan="1" colspan="1">28.0</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Dysmenorrhoea</td>
                        <td align="right" rowspan="1" colspan="1">5</td>
                        <td align="right" rowspan="1" colspan="1">10,0</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Hypermenorrhoea, dysmenorrhoea, pain</td>
                        <td align="right" rowspan="1" colspan="1">4</td>
                        <td align="right" rowspan="1" colspan="1">8.0</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Hypermenorrhoea, dysmenorrhoea, growing myomas</td>
                        <td align="right" rowspan="1" colspan="1">4</td>
                        <td align="right" rowspan="1" colspan="1">8.0</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">growing myomas, dysmenorrhoea</td>
                        <td align="right" rowspan="1" colspan="1">2</td>
                        <td align="right" rowspan="1" colspan="1">4.0</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Growing myomas, pain</td>
                        <td align="right" rowspan="1" colspan="1">4</td>
                        <td align="right" rowspan="1" colspan="1">8.0</td>
                     </tr>
                     <tr>
                        <th rowspan="1" colspan="1">Total</th>
                        <th align="right" rowspan="1" colspan="1">50</th>
                        <th align="right" rowspan="1" colspan="1">100.0</th>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
            <p>The aim of our study was to obtain further knowledge on the use of new medication for preoperative treatment of myomas, since so far such studies have been rather scarce and performed mostly in patients with heavy myoma-related bleedings but not also in those with other symptoms. We were particularly interested in the effect of UPA on the reduction of myoma and the improvement of blood counts, as the research so far was focused primarily on reducing bleeding and improving the quality of life.</p>
         </sec>
         <sec id="en-s2" sec-type="Subjects and methods">
            <label>2</label>
            <title>Subjects and methods</title>
            <sec id="en-s2.1" sec-type="Subjects and measurements">
               <label>2.1</label>
               <title>Subjects and measurements</title>
               <p>Our prospective non-randomised study was carried out at the Department of Human Reproduction, Division of Gynaecology of the University Medical Centre Ljubljana in the period between October 2013 and December 2016. The study group consisted of 50 patients with myomas and symptoms who required surgical treatment. Additional criteria for inclusion were as follows: the largest myoma diameter more than 3 cm and functional ovaries. Postmenopausal patients, patients with unexplained uterine bleedings and those who had been receiving hormone replacement therapy in the last six months were not included in the study. The study group subjects were aged 26–57 years (mean 43.4 years, SD 7.33).</p>
               <p>Prior to the planned surgical intervention, all patients were prescribed UPA at a dosage of 5 mg/day through 12 weeks, which was to be taken in the first 4 days of their menstrual cycle in accordance with the prescribing instructions.</p>
               <fig position="anchor" id="en-fig2" orientation="portrait">
                  <label>Figure 2:</label>
                  <caption>
                     <p> Median (1<sup>st</sup> and 3<sup>rd</sup> quartile, min/max.) increase in Hb concentration after completed UPA treatment.</p>
                  </caption>
                  <p>
                     <graphic xlink:href="2633-en-web-resources/image/zdravvestn-2633-en-02.png"
                              position="float"
                              orientation="portrait"/>
                  </p>
               </fig>
               <p>All of them had haemoglobin concentration determined before the beginning of therapy. Anaemic patients were additionally prescribed an iron supplement in form of tablets (100 mg of ferric oxide per day), if it had not been already prescribed by their selected physician. Prior to the beginning of UPA treatment, all patients included in the study underwent ultrasonography (US) to have the diameters of up to 3 largest myomas measured in 2 planes. The mean diameter served as the basis for calculating the volume of up to 3 largest myomas using the formula for the volume of a sphere (V = 4/3πr<sup>3</sup>). One to two weeks after completed UPA treatment, the same US measurements of up to 3 largest myomas were repeated and Hb concentration re-determined.</p>
               <p>In all subjects we monitored the parameters that were relevant for assessing the effectiveness of preoperative UPA treatment: change in the volume of all measured myomas and the largest myoma, change in uterine bleeding during therapy, change in Hb concentration, and any side effects were recorded. At the end of the treatment, the endometrial thickness was evaluated by ultrasonography, and in patients who underwent hysterectomy, the tissue was histologically examined.</p>
               <p>Taking into account possible measurement errors, UPA treatment was considered successful in those patients in whom the total myoma volume was reduced by at least 10 %. In Week 13 to 16 from the beginning of UPA treatment all patients underwent laparoscopic surgery. The type of surgical intervention was determined with respect to the number of myomas, possible former surgeries for myoma, patient’s age, desire for conception and preservation of the uterus. Four patients (8.0 %) had total laparoscopic hysterectomy (TLH), 25 (50.0 %) supracervical laparoscopic hysterectomy (SLH) and 21 (40.0 %) had laparoscopic myomectomy. As many as 14 (28.0 %) patients wished to get pregnant after completed therapy while 7 (14.0 %) only wished to have their uterus preserved. In patients with only myoma removal, we subjectively assessed the cleavage plane between myoma and the myometrium, or the difficulty of myoma enucleation and its consistency.</p>
               <table-wrap position="anchor" id="en-table2" orientation="portrait">
                  <label>Table 2:</label>
                  <caption>
                     <p> Volume change of the largest myoma and total myoma volume change in ml and percentages before the beginning and after competed UPA treatment. Data are expressed as mean volume (standard deviation) and 95 % confidence interval (CI) for volume change in ml and the percentage change in %.</p>
                  </caption>
                  <table>
                     <colgroup span="1">
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                     </colgroup>
                     <thead>
                        <tr>
                           <th rowspan="1" colspan="1">Myoma volume</th>
                           <th rowspan="1" colspan="1">Before UPA (ml)</th>
                           <th rowspan="1" colspan="1">After UPA (ml)</th>
                           <th rowspan="1" colspan="1">Dvol. (ml)</th>
                           <th rowspan="1" colspan="1">95 % CI (Dvol. in ml)</th>
                           <th rowspan="1" colspan="1">p (Dvol. in ml)</th>
                           <th rowspan="1" colspan="1">Dvol. (%)</th>
                           <th rowspan="1" colspan="1">95 % CI (Dvol. in %)</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td rowspan="1" colspan="1">The largest</td>
                           <td align="right" rowspan="1" colspan="1">153.6 (178.0)</td>
                           <td align="right" rowspan="1" colspan="1">97.7 (132.6)</td>
                           <td align="right" rowspan="1" colspan="1">-56.0 (133.3)</td>
                           <td align="right" rowspan="1" colspan="1">[-93.0; -19.1]</td>
                           <td align="right" rowspan="1" colspan="1">0.004</td>
                           <td align="right" rowspan="1" colspan="1">-33.3 (30.5)</td>
                           <td align="right" rowspan="1" colspan="1">[-41.8; -24.9]</td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">Min/Max</td>
                           <td align="right" rowspan="1" colspan="1">11.0/927.1</td>
                           <td align="right" rowspan="1" colspan="1">6.0/833.9</td>
                           <td align="right" rowspan="1" colspan="1">278.5/-767.3</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">50.1/-82.7</td>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">Total 3 largest</td>
                           <td align="right" rowspan="1" colspan="1">191.7 (197.4)</td>
                           <td align="right" rowspan="1" colspan="1">123.5 (144.5)</td>
                           <td align="right" rowspan="1" colspan="1">-68.0 (145,5)</td>
                           <td align="right" rowspan="1" colspan="1">[-108.3; -27.7]</td>
                           <td align="right" rowspan="1" colspan="1">0.002</td>
                           <td align="right" rowspan="1" colspan="1">-32.3 (32.6)</td>
                           <td align="right" rowspan="1" colspan="1">[-41.3–23.3]</td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">Min/Max</td>
                           <td align="right" rowspan="1" colspan="1">14.7/1074.6</td>
                           <td align="right" rowspan="1" colspan="1">10.3/518.4</td>
                           <td align="right" rowspan="1" colspan="1">282.2/-822.3</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">47.2/-79.2</td>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                     </tbody>
                  </table>
               </table-wrap>
               <p>All the US measurements and surgeries were performed by the first author of this article.</p>
               <p>As our study covered only preoperative treatment with a drug that has already been registered for this type of therapy while all other procedures were compliant with the routine used in other patients scheduled for myoma surgery, an ethical assessment of the research was not required.</p>
            </sec>
            <sec id="en-s2.2" sec-type="Statistical methods">
               <label>2.2</label>
               <title>Statistical methods</title>
               <p>The normal distribution of the observed variables was verified by Shapiro-Wilk’s test. Since the variables were distributed normally, the results were shown as averages with a standard deviation (SD). The difference in myoma volume before and after UPA treatment, and the difference in Hb concentration before and after treatment were tested with dependent t-test for paired samples. Confidence intervals were calculated. Statistical analyses were performed using Statistica 8.0 software (StatSoft Inc.). Statistical significance cut-off value was set to p &lt; 0.05.</p>
            </sec>
         </sec>
         <sec id="en-s3" sec-type="Results">
            <label>3</label>
            <title>Results</title>
            <p>
               <xref ref-type="table" rid="en-table1">Table 1</xref> presents indications for surgery in study patients. Fourteen patients (28.0 %) had 1 myoma, 9 (18 %) had 2 and 27 patients (54.0 %) had 3 or more myomas. Out of 50 patients, 41 (82.0 %) were anaemic with Hb concentration lower than 120 g/L.</p>
            <p>During UPA treatment, 41 (82.5 %) patients were amenorrhoeic while the remaining 9 (18.0 %) had only light cyclical bleedings.</p>
            <p>After completed UPA treatment, the mean volume of the largest myoma decreased by 33.3 % (95 % CI [-41.8; -24.9]) and the total mean volume of 3 largest myomas by 32.3 % (95 % CI [-41,3; -23,3]). In both cases, the volume decrease was statistically significant (<xref ref-type="table" rid="en-table2">Table 2</xref>).</p>
            <table-wrap position="anchor" id="en-table3" orientation="portrait">
               <label>Table 3:</label>
               <caption>
                  <p> Adverse side effects in individual patients.</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Patient</th>
                        <th rowspan="1" colspan="1">Hot flashes</th>
                        <th rowspan="1" colspan="1">Headache</th>
                        <th rowspan="1" colspan="1">Breast swelling</th>
                        <th rowspan="1" colspan="1">Loss of appetite</th>
                        <th rowspan="1" colspan="1">Mild hair loss</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>1</p>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>2</p>
                        </td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>3</p>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>4</p>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>5</p>
                        </td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>6</p>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>7</p>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>8</p>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>9</p>
                        </td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>10</p>
                        </td>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>11</p>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">+</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
            <p>In 37 (74.0 %) patients the mean myoma volume decreased by more than 10 %. In these patients after completed UPA treatment, the mean volume of the largest myoma decreased by 47.6 % (95 % CI [-53.3; -41.9]) and the total mean volume of 3 largest myomas by 48.5 % (95 % CI [-54.0; -43.0]).</p>
            <p>
               <xref ref-type="fig" rid="en-fig1">Figure 1</xref> shows the median change in the sum of volumes, the first and third quartiles, and the lowest and highest values in percentages of up to 3 largest myomas.</p>
            <p>In all subjects we noted an increase in the concentration of Hb by 24.3 g/l on average (from 5 to 76 g/l, SD 16.32 g/l, 95 % CI [19.8; 28.8]), the difference being statistically significant (p &lt; 0.001). <xref ref-type="fig" rid="en-fig2">Figure 2</xref> shows an increase in the concentration of Hb after completed UPA treatment.</p>
            <p>Adverse side effects were noted in 11 (22.0 %) patients (<xref ref-type="table" rid="en-table3">Table 3</xref>). None of the patients with side effects sought medical help or discontinued their UPA treatment. Four (8.0 %) of the patients experienced mild hot flashes, 7 (14.0 %) mild to moderate occasional headache, 3 (6.0 %) experienced breast swelling, and 1 (2.0 %) patient reported loss of appetite and mild hair loss. Multiple side effects were reported by 4 (8.0 %) patients. After completed UPA treatment, ultrasonography revealed endometrial thickening (&gt; 16 mm) in 7 (14.0 %) patients. In four of them who underwent hysterectomy PAEC was histologically confirmed while the remaining 3 only had myomas removed and therefore histological examination of the endometrium was not performed.</p>
            <p>In patients with myomectomy the cleavage plane between fibroids and the myometrium was well preserved. We have also noted that in UPA treated patients myomas are slightly softer than in those who do not receive preoperative UPA treatment.</p>
         </sec>
         <sec id="en-s4" sec-type="Discussion">
            <label>4</label>
            <title>Discussion</title>
            <p>Presently, medical treatment of myomas most frequently precedes the planned surgery in order to reduce myoma volume and improve the patient’s blood count, as well as for research purposes (<xref ref-type="bibr" rid="en-b20">20</xref>,<xref ref-type="bibr" rid="en-b21">21</xref>). Our study has shown that a preoperative UPA treatment efficiently reduces myoma volume in the majority of patients, thus facilitating or even enabling the endoscopic surgery. Not only the duration of surgery is shorter in smaller myomas but the myoma size may also influence the loss of blood during the procedure (<xref ref-type="bibr" rid="en-b22">22</xref>,<xref ref-type="bibr" rid="en-b23">23</xref>). Despite the fact that ours was not a randomised controlled study, which is undoubtedly a drawback, the results are nevertheless similar to those obtained in groups of study subjects receiving the same dose of UPA in the few randomised controlled studies that have been performed to date by a single research group.</p>
            <p>An advantage of our study is that – for the difference from PEARL studies which included only patients with hypermenorrhoea and myomas smaller than 100 mm – our study also included patients with myomas exceeding 100 mm in diameter and with other myoma-related symptoms. The authors of studies PERL II and IV have found that preoperative UPA treatment effectively decreases myoma volume. The total volume of the three largest myomas decreased by 36 % and 38 % (median) in 97 and 228 subjects respectively, receiving UPA at a dose of 5 mg. In 50 subjects in our study, the total volume of the largest myomas was found to have decreased by 32.3 % on average (95 % CI [-41.3; -23.3]) (<xref ref-type="bibr" rid="en-b15">15</xref>,<xref ref-type="bibr" rid="en-b24">24</xref>).</p>
            <p>No difficulties were encountered in patients with myomectomy as the cleavage plane between myomas and the myometrium was well preserved. We have noted, however, that in UPA treated patients myomas were slightly softer than in those who did not receive preoperative UPA treatment. These subjective findings were also confirmed by other investigators participating in the studies where patients received preoperative UPA treatment (<xref ref-type="bibr" rid="en-b25">25</xref>). According to our treatment success criteria requiring at least a 10 % myoma volume reduction, the treatment was unsuccessful in 26.0 % of the patients. A recent research has shown that UPA treatment in younger patients and/or those with large myomas could be unsuccessful (<xref ref-type="bibr" rid="en-b8">8</xref>).</p>
            <p>After UPA treatment, all our study patients presented with a statistically significant increase in Hb concentration. During treatment, most of them (82.0 %) were amenorrhoeic, while the others presented with significantly decreased bleeding and as a result of that an improved or normalised blood count, which was consisted with the findings of Donnez et al. (<xref ref-type="bibr" rid="en-b15">15</xref>,<xref ref-type="bibr" rid="en-b19">19</xref>). A recent study has shown that outcomes of non-cardiac surgical procedures are worse in anaemic patients. Namely, even a low-grade anaemia (haematocrit in females &lt; 36 %) significantly affects 30-day postoperative morbidity and mortality in patients who underwent a major non-cardiac surgery (<xref ref-type="bibr" rid="en-b26">26</xref>).</p>
            <p>UPA medication is available in the form of 5 mg tablets. The medicine is taken once a day for 12 weeks and the application starts in the first week of menstrual bleeding. This three-month treatment cycle can be repeated several times. Re-treatment starts during the second menstrual period after the completed previous treatment cycle. Menstruations are generally restored within 4 weeks from the completed treatment (<xref ref-type="bibr" rid="en-b27">27</xref>). The most frequent side effect of UPA treatment is amenorrhoea, which however is desirable. Other frequent adverse effects include headache, fatigue, nausea, abdominal pain, dizziness, acnae, muscular and skeletal pains, hot flushes, ovarian cysts and breast tenderness. UPA is not recommended in patients with severe renal impairment, with moderate or severe hepatic insufficiency, and in patients under 18 years of age. The use is further contraindicated in the case of hypersensitivity to the active substance or to any of the excipients, in women who are pregnant or breastfeeding, who bleed from the genitals for unknown reason or cause unrelated to uterine myoma, and in patients with cervical, ovarian or breast cancer (<xref ref-type="bibr" rid="en-b28">28</xref>).</p>
            <p>In its document EMA/355940/2018, Pharmacovigilance Risk Assessment Committee (PRAC) at the European Agency for Medicines published recommendations on measures to reduce the risk of complications arising from possible hepatotoxicity of UPA, which were adopted by the Committee for Medicinal Products for Human Use (CHMP) on 1 June 2018.</p>
            <p>Before starting UPA treatment, all patients must undergo liver function tests. If the value of liver enzymes is twofold the upper normal value, this medicine must not be prescribed. Functional liver tests should be repeated every month in the course of therapy, and then 2–4 weeks after completed treatment. If the values of liver enzymes are three times above the upper normal value, the treatment should be discontinued and the patient carefully monitored. Multiple UPA cycles should only be prescribed to patients who are not eligible for surgery. Prior to the planned surgery, only one cycle of UPA should be prescribed (<xref ref-type="bibr" rid="en-b29">29</xref>).</p>
            <p>In our study, in most patients, amenorrhea or a significant reduction in uterine bleeding was achieved within a short time, which was the desired effect. Approximately a fifth of the patients reported mild adverse side effects, most often a headache, which is comparable to other studies (<xref ref-type="bibr" rid="en-b12">12</xref>,<xref ref-type="bibr" rid="en-b15">15</xref>,<xref ref-type="bibr" rid="en-b19">19</xref>,<xref ref-type="bibr" rid="en-b24">24</xref>).</p>
            <p>The use of UPA has been studied in PEARL I, PEARL II, PEARL III, PEARL III extension, and PEARL IV clinical trials. In PEARL I, researchers compared the use of UPA and placebo in patients with symptoms, who were planned to undergo surgery. All of them were receiving iron and UPA at a dosage of 5 mg/day (96 subjects) or 10 mg/day (98 subjects) or placebo (48 subjects) for 12 weeks. The amount of uterine bleeding, the blood count before and after treatment and the size of myomas were monitored. It was found that both dosage regimens of UPA treatment effectively controlled uterine bleeding (most patients were amenorrhoeic after 10 days of UPA use), improved blood count and reduced the median myoma volume by 21 % (<xref ref-type="bibr" rid="en-b19">19</xref>).</p>
            <p>In PEARL II trial, the effectiveness of UPA 5 mg (97 subjects) or 10 mg (103 subjects) was compared to GnRHa leuprolide acetate (101 subjects) for preoperative treatment of symptomatic myomas. It was found that the difference between two groups of subjects who received 5 mg or10 mg of UPA per day was not statistically significant compared to monthly injections of leuprolide acetate to reduce uterine haemorrhage due to myoma. Bleeding was found to have decreased in 90.0 % of patients receiving 5 mg UPA, in 98.0 % of patients receiving 10 mg UPA, and in 89 % of patients receiving leuprolide acetate. Furthermore, the patients receiving UPA had significantly fewer hot flashes (10.0 % and 11.0 % respectively in UPA groups vs. 40.0 % in leuprolide acetate group). The preliminary results also showed a prolonged effect of myoma volume reduction in non-operated-on patients. In the leuprolide acetate group, myomas started to regrow already a month after the last dose, while in the UPA groups, most patients showed no evidence of myomas regrowth after 6 months (<xref ref-type="bibr" rid="en-b15">15</xref>).</p>
            <p>PEARL III (209 subjects) and PEARL III extension (132 subjects) trials were carried out to establish the efficacy and safety of long-term use of UPA for the treatment of patients with symptomatic myomas. In most patients, 4 cycles of UPA taken with intermittent pauses resulted in amenorrhoea and a further decrease in myoma size. These data indicate that UPA may trigger apoptosis and reduce myoma cell proliferation, which could result in regression of the disease (<xref ref-type="bibr" rid="en-b12">12</xref>,<xref ref-type="bibr" rid="en-b14">14</xref>,<xref ref-type="bibr" rid="en-b19">19</xref>).</p>
            <p>In PEARL IV too, likewise in former two trials, the authors tested the efficacy and safety of long-term UPA use in patients with symptomatic myomas. The study subjects received 5 mg (228 subjects) or 10 mg (223 subjects) of UPA for 12 weeks with intermittent pauses so that they started taking UPA again during the second menstruation following a completed previous cycle. During UPA use, the majority of patients in both groups were amenorrhoeic (69.6 % and 74.5 % respectively). The difference between the groups with 5 mg and 10 mg UPA was not statistically significant. In both groups, the myoma volume was reduced by 25 % or more in 78.0 % and 80.1 % of patients respectively, the difference also not being statistically significant. This study further confirmed the efficacy and safety of long-term treatment with UPA (<xref ref-type="bibr" rid="en-b13">13</xref>,<xref ref-type="bibr" rid="en-b24">24</xref>).</p>
            <p>The first few successful pregnancies were reported in a follow-up study of the patients who participated in PEARL II and PEARL III clinical trials, and who later on wanted to become pregnant. Following preoperative UPA treatment, as many as 21 patients wanted to become pregnant, and 15 (71.0 %) of them succeeded. Thirteen healthy children were born (12 deliveries), while 6 women had spontaneous abortion in the early pregnancy. In two pregnant patients, myomas disappeared almost completely, so that surgery was deemed unnecessary. The researchers also did not notice any regrowth of myomas in pregnancy, which indicates a prolonged effect of myoma size reduction (<xref ref-type="bibr" rid="en-b30">30</xref>). A few cases of successful pregnancies after UPA treatment of symptomatic myomas without the need for subsequent surgery have been described (<xref ref-type="bibr" rid="en-b31">31</xref>,<xref ref-type="bibr" rid="en-b32">32</xref>).</p>
         </sec>
         <sec id="en-s5" sec-type="Conclusions">
            <label>5</label>
            <title>Conclusions</title>
            <p>Our research has shown that preoperative UPA treatment efficiently reduces the size of myomas and improves blood count, which facilitates or enables the use of the most advanced methods of endoscopic surgery and reduces the risk of postoperative complications. Despite the shortcomings of this study, which was not a randomised controlled one, the results are in line with those obtained by the few randomised controlled trials that have been carried out so far. In our, as well as in other studies, UPA was tolerated well by the patients, and had relatively few side effects. Nevertheless, a lot of further research on the efficacy and, above all, of the safety of UPA will have to be carried out, as in the recent months there has been a suspicion of possible hepatotoxicity of this medicinal product.</p>
         </sec>
      </body>
      <back>
         <ref-list>
            <ref id="en-b1">
               <label>1. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Marshall</surname>
                        <given-names>LM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Spiegelman</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Barbieri</surname>
                        <given-names>RL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Goldman</surname>
                        <given-names>MB</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Manson</surname>
                        <given-names>JE</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Colditz</surname>
                        <given-names>GA</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Variation in the incidence of uterine leiomyoma among premenopausal women by age and race</article-title>. 
                    <source>Obstet Gynecol</source>. 
                    <year>1997</year>
                    <month>Dec</month>;
                    <volume>90</volume>(
                    <issue>6</issue>):
                    <fpage>967</fpage>–
                    <lpage>73</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0029-7844(97)00534-6</pub-id>
                    <pub-id pub-id-type="pmid">9397113</pub-id>
                    <issn>0029-7844</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b2">
               <label>2. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Sabry</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Al-Hendy</surname>
                        <given-names>A</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Medical treatment of uterine leiomyoma</article-title>. 
                    <source>Reprod Sci</source>. 
                    <year>2012</year>
                    <month>Apr</month>;
                    <volume>19</volume>(
                    <issue>4</issue>):
                    <fpage>339</fpage>–
                    <lpage>53</lpage>. 
                    <pub-id pub-id-type="doi">10.1177/1933719111432867</pub-id>
                    <pub-id pub-id-type="pmid">22378865</pub-id>
                    <issn>1933-7191</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b3">
               <label>3. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Parker</surname>
                        <given-names>WH</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Uterine myomas: management</article-title>. 
                    <source>Fertil Steril</source>. 
                    <year>2007</year>
                    <month>Aug</month>;
                    <volume>88</volume>(
                    <issue>2</issue>):
                    <fpage>255</fpage>–
                    <lpage>71</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.fertnstert.2007.06.044</pub-id>
                    <pub-id pub-id-type="pmid">17658523</pub-id>
                    <issn>0015-0282</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b4">
               <label>4. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Talaulikar</surname>
                        <given-names>VS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Manyonda</surname>
                        <given-names>I</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids</article-title>. 
                    <source>Eur J Obstet Gynecol Reprod Biol</source>. 
                    <year>2012</year>
                    <month>Dec</month>;
                    <volume>165</volume>(
                    <issue>2</issue>):
                    <fpage>135</fpage>–
                    <lpage>40</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ejogrb.2012.07.023</pub-id>
                    <pub-id pub-id-type="pmid">22901974</pub-id>
                    <issn>0301-2115</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b5">
               <label>5. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Sankaran</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Manyonda</surname>
                        <given-names>IT</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Medical management of fibroids</article-title>. 
                    <source>Best Pract Res Clin Obstet Gynaecol</source>. 
                    <year>2008</year>
                    <month>Aug</month>;
                    <volume>22</volume>(
                    <issue>4</issue>):
                    <fpage>655</fpage>–
                    <lpage>76</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.bpobgyn.2008.03.001</pub-id>
                    <pub-id pub-id-type="pmid">18468953</pub-id>
                    <issn>1521-6934</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b6">
               <label>6. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Trefoux Bourdet</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Luton</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Koskas</surname>
                        <given-names>M</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence</article-title>. 
                    <source>Int J Womens Health</source>. 
                    <year>2015</year>
                    <month>Mar</month>;
                    <volume>7</volume>:
                    <fpage>321</fpage>–
                    <lpage>30</lpage>.
                    <pub-id pub-id-type="doi">10.2147/IJWH.S50016</pub-id>
                    <pub-id pub-id-type="pmid">25848323</pub-id>
                    <issn>1179-1411</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b7">
               <label>7. </label>
               <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Ribič-Pucelj</surname>
                        <given-names>M</given-names>
                     </name>,
                        <name name-style="western">
                        <surname>Tomaževič</surname>
                        <given-names>T</given-names>
                     </name>,
                        <name name-style="western">
                        <surname>Vogler</surname>
                        <given-names>A</given-names>
                     </name>
                    </person-group>.  
                    <chapter-title>Laparoskopska miomektomija</chapter-title>. In:
                    <person-group person-group-type="editor">
                        <name name-style="western">
                        <surname>Ribič-Pucelj</surname>
                        <given-names>M</given-names>
                     </name>,
                        <name name-style="western">
                        <surname>Pegan</surname>
                        <given-names>V</given-names>
                     </name>,
                        <name name-style="western">
                        <surname>Pašić</surname>
                        <given-names>RP</given-names>
                     </name>
                    </person-group>.
                    <source>Endoskopske operacije v ginekologiji</source>.
                    <publisher-loc>Radovljica</publisher-loc>:
                    <publisher-name>Didakta</publisher-name>;
                    <year>2007</year>. pp. 
                    <fpage>207</fpage>–
                    <lpage>15</lpage>.
                </mixed-citation>
            </ref>
            <ref id="en-b8">
               <label>8. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Brun</surname>
                        <given-names>JL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Rajaonarison</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Froeliger</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Monseau-Thiburce</surname>
                        <given-names>AC</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Randriamboavonjy</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Vogler</surname>
                        <given-names>A</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy</article-title>. 
                    <source>Eur J Obstet Gynecol Reprod Biol</source>. 
                    <year>2018</year>
                    <month>Mar</month>;
                    <volume>222</volume>:
                    <fpage>13</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ejogrb.2017.12.033</pub-id>
                    <pub-id pub-id-type="pmid">29328939</pub-id>
                    <issn>0301-2115</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b9">
               <label>9. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Sinai Talaulikar</surname>
                        <given-names>V</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Belli</surname>
                        <given-names>AM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Manyonda</surname>
                        <given-names>I</given-names>
                     </name>
                    </person-group>. 
                    <article-title>GnRH agonists: do they have a place in the modern management of fibroid disease?</article-title>
                    <source>J Obstet Gynaecol India</source>. 
                    <year>2012</year>
                    <month>Oct</month>;
                    <volume>62</volume>(
                    <issue>5</issue>):
                    <fpage>506</fpage>–
                    <lpage>10</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s13224-012-0206-0</pub-id>
                    <pub-id pub-id-type="pmid">24082548</pub-id>
                    <issn>0022-3190</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b10">
               <label>10. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Lethaby</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Vollenhoven</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Sowter</surname>
                        <given-names>M</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review</article-title>. 
                    <source>BJOG</source>. 
                    <year>2002</year>
                    <month>Oct</month>;
                    <volume>109</volume>(
                    <issue>10</issue>):
                    <fpage>1097</fpage>–
                    <lpage>108</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1471-0528.2002.01225.x</pub-id>
                    <pub-id pub-id-type="pmid">12387461</pub-id>
                    <issn>1470-0328</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b11">
               <label>11. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Mavrelos</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ben-Nagi</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Davies</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Lee</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Salim</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Jurkovic</surname>
                        <given-names>D</given-names>
                     </name>
                    </person-group>. 
                    <article-title>The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo-controlled randomized trial</article-title>. 
                    <source>Hum Reprod</source>. 
                    <year>2010</year>
                    <month>Sep</month>;
                    <volume>25</volume>(
                    <issue>9</issue>):
                    <fpage>2264</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/humrep/deq188</pub-id>
                    <pub-id pub-id-type="pmid">20663795</pub-id>
                    <issn>0268-1161</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b12">
               <label>12. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Donnez</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Vázquez</surname>
                        <given-names>F</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Tomaszewski</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Nouri</surname>
                        <given-names>K</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bouchard</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Fauser</surname>
                        <given-names>BC</given-names>
                     </name>, 
                        <etal>et al</etal>; 
                        <collab>PEARL III and PEARL III Extension Study Group</collab>
                    </person-group>. 
                    <article-title>Long-term treatment of uterine fibroids with ulipristal acetate</article-title>. 
                    <source>Fertil Steril</source>. 
                    <year>2014</year>
                    <month>Jun</month>;
                    <volume>101</volume>(
                    <issue>6</issue>):
                    <fpage>1565</fpage>–
                    <lpage>73.e1</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.fertnstert.2014.02.008</pub-id>
                    <pub-id pub-id-type="pmid">24630081</pub-id>
                    <issn>0015-0282</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b13">
               <label>13. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Donnez</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Donnez</surname>
                        <given-names>O</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Matule</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ahrendt</surname>
                        <given-names>HJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Hudecek</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zatik</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Long-term medical management of uterine fibroids with ulipristal acetate</article-title>. 
                    <source>Fertil Steril</source>. 
                    <year>2016</year>
                    <month>Jan</month>;
                    <volume>105</volume>(
                    <issue>1</issue>):
                    <fpage>165</fpage>–
                    <lpage>173.e4</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.fertnstert.2015.09.032</pub-id>
                    <pub-id pub-id-type="pmid">26477496</pub-id>
                    <issn>0015-0282</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b14">
               <label>14. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Powell</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Dutta</surname>
                        <given-names>D</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Esmya
                        <sup>®</sup> and the PEARL studies: A review
                    </article-title>. 
                    <source>Womens Health (Lond)</source>. 
                    <year>2016</year>
                    <month>Nov</month>;
                    <volume>12</volume>(
                    <issue>6</issue>):
                    <fpage>544</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1177/1745505717692591</pub-id>
                    <pub-id pub-id-type="pmid">29334010</pub-id>
                    <issn>1745-5065</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b15">
               <label>15. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Donnez</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Tomaszewski</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Vázquez</surname>
                        <given-names>F</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bouchard</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Lemieszczuk</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Baró</surname>
                        <given-names>F</given-names>
                     </name>, 
                        <etal>et al</etal>; 
                        <collab>PEARL II Study Group</collab>
                    </person-group>. 
                    <article-title>Ulipristal acetate versus leuprolide acetate for uterine fibroids</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2012</year>
                    <month>Feb</month>;
                    <volume>366</volume>(
                    <issue>5</issue>):
                    <fpage>421</fpage>–
                    <lpage>32</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1103180</pub-id>
                    <pub-id pub-id-type="pmid">22296076</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b16">
               <label>16. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Biglia</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Carinelli</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Maiorana</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>D’Alonzo</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Lo Monte</surname>
                        <given-names>G</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Marci</surname>
                        <given-names>R</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids</article-title>. 
                    <source>Drug Des Devel Ther</source>. 
                    <year>2014</year>
                    <month>Feb</month>;
                    <volume>8</volume>:
                    <fpage>285</fpage>–
                    <lpage>92</lpage>.
                    <pub-id pub-id-type="doi">10.2147/DDDT.S54565</pub-id>
                    <pub-id pub-id-type="pmid">24591818</pub-id>
                    <issn>1177-8881</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b17">
               <label>17. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Fiscella</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bonfiglio</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Winters</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Eisinger</surname>
                        <given-names>SH</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Fiscella</surname>
                        <given-names>K</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone</article-title>. 
                    <source>Hum Pathol</source>. 
                    <year>2011</year>
                    <month>Jul</month>;
                    <volume>42</volume>(
                    <issue>7</issue>):
                    <fpage>947</fpage>–
                    <lpage>53</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.humpath.2010.11.003</pub-id>
                    <pub-id pub-id-type="pmid">21315422</pub-id>
                    <issn>0046-8177</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b18">
               <label>18. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Williams</surname>
                        <given-names>AR</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bergeron</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Barlow</surname>
                        <given-names>DH</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ferenczy</surname>
                        <given-names>A</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate</article-title>. 
                    <source>Int J Gynecol Pathol</source>. 
                    <year>2012</year>
                    <month>Nov</month>;
                    <volume>31</volume>(
                    <issue>6</issue>):
                    <fpage>556</fpage>–
                    <lpage>69</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/PGP.0b013e318251035b</pub-id>
                    <pub-id pub-id-type="pmid">23018219</pub-id>
                    <issn>0277-1691</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b19">
               <label>19. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Donnez</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Tatarchuk</surname>
                        <given-names>TF</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bouchard</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Puscasiu</surname>
                        <given-names>L</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zakharenko</surname>
                        <given-names>NF</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ivanova</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <etal>et al</etal>; 
                        <collab>PEARL I Study Group</collab>
                    </person-group>. 
                    <article-title>Ulipristal acetate versus placebo for fibroid treatment before surgery</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2012</year>
                    <month>Feb</month>;
                    <volume>366</volume>(
                    <issue>5</issue>):
                    <fpage>409</fpage>–
                    <lpage>20</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1103182</pub-id>
                    <pub-id pub-id-type="pmid">22296075</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b20">
               <label>20. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Sabry</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Al-Hendy</surname>
                        <given-names>A</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Innovative oral treatments of uterine leiomyoma</article-title>. 
                    <source>Obstet Gynecol Int</source>. 
                    <year>2012</year>;
                    <volume>2012</volume>:
                    <fpage>943635</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2012/943635</pub-id>
                    <pub-id pub-id-type="pmid">22518167</pub-id>
                    <issn>1687-9589</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b21">
               <label>21. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Duhan</surname>
                        <given-names>N</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Current and emerging treatments for uterine myoma - an update</article-title>. 
                    <source>Int J Womens Health</source>. 
                    <year>2011</year>;
                    <volume>3</volume>(
                    <issue>1</issue>):
                    <fpage>231</fpage>–
                    <lpage>41</lpage>. 
                    <pub-id pub-id-type="doi">10.2147/IJWH.S15710</pub-id>
                    <pub-id pub-id-type="pmid">21892334</pub-id>
                    <issn>1179-1411</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b22">
               <label>22. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Ginsburg</surname>
                        <given-names>ES</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Benson</surname>
                        <given-names>CB</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Garfield</surname>
                        <given-names>JM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Gleason</surname>
                        <given-names>RE</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Friedman</surname>
                        <given-names>AJ</given-names>
                     </name>
                    </person-group>. 
                    <article-title>The effect of operative technique and uterine size on blood loss during myomectomy: a prospective randomized study</article-title>. 
                    <source>Fertil Steril</source>. 
                    <year>1993</year>
                    <month>Dec</month>;
                    <volume>60</volume>(
                    <issue>6</issue>):
                    <fpage>956</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0015-0282(16)56392-4</pub-id>
                    <pub-id pub-id-type="pmid">8243699</pub-id>
                    <issn>0015-0282</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b23">
               <label>23. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Leone Roberti Maggiore</surname>
                        <given-names>U</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Scala</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Venturini</surname>
                        <given-names>PL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ferrero</surname>
                        <given-names>S</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Preoperative treatment with letrozole in patients undergoing laparoscopic myomectomy of large uterine myomas: a prospective non-randomized study</article-title>. 
                    <source>Eur J Obstet Gynecol Reprod Biol</source>. 
                    <year>2014</year>
                    <month>Oct</month>;
                    <volume>181</volume>:
                    <fpage>157</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ejogrb.2014.07.040</pub-id>
                    <pub-id pub-id-type="pmid">25150954</pub-id>
                    <issn>0301-2115</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b24">
               <label>24. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Donnez</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Hudecek</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Donnez</surname>
                        <given-names>O</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Matule</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Arhendt</surname>
                        <given-names>HJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zatik</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids</article-title>. 
                    <source>Fertil Steril</source>. 
                    <year>2015</year>
                    <month>Feb</month>;
                    <volume>103</volume>(
                    <issue>2</issue>):
                    <fpage>519</fpage>–
                    <lpage>27.e3</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.fertnstert.2014.10.038</pub-id>
                    <pub-id pub-id-type="pmid">25542821</pub-id>
                    <issn>0015-0282</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b25">
               <label>25. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Rabe</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ahrendt</surname>
                        <given-names>HJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Albring</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bitzer</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bouchard</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Cirkel</surname>
                        <given-names>U</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Ulipristal acetate for symptomatic uterine fibroids and myoma-related hypermenorrhea: joint statement by the german society for gynecological endocrinology and reproductive medicine (DGGEF) and the german professional association of gynecologist (BVF)</article-title>. 
                    <source>J Reproduktionsmed Endokrinol</source>.
                    <year>2013</year>;
                    <volume>10</volume>(
                    <issue>Special Issue 1</issue>):
                    <fpage>82</fpage>–
                    <lpage>101</lpage>.
                </mixed-citation>
            </ref>
            <ref id="en-b26">
               <label>26. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Musallam</surname>
                        <given-names>KM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Tamim</surname>
                        <given-names>HM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Richards</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Spahn</surname>
                        <given-names>DR</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Rosendaal</surname>
                        <given-names>FR</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Habbal</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study</article-title>. 
                    <source>Lancet</source>. 
                    <year>2011</year>
                    <month>Oct</month>;
                    <volume>378</volume>(
                    <issue>9800</issue>):
                    <fpage>1396</fpage>–
                    <lpage>407</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0140-6736(11)61381-0</pub-id>
                    <pub-id pub-id-type="pmid">21982521</pub-id>
                    <issn>0140-6736</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b27">
               <label>27. </label>
               <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <collab>European medicines agency. Science medicines health</collab>.
                    </person-group>.
                    <source>Esmya (ulipristalacetat)</source>. 
                    <comment>Available from:<uri>http://www.ema.europa.eu/docs/sl_SI/document_library/EPAR_-_Summary_for_the_public/human/002041/WC500124089.pdf</uri>
                  </comment>. 
                </mixed-citation>
            </ref>
            <ref id="en-b28">
               <label>28. </label>
               <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <collab>European medicines agency. Science medicines health</collab>.
                    </person-group>.
                    <source>Priloga 1. Povzetek glavnih značilnosti zdravila</source>. 
                    <comment>Available from:<uri>http://www.ema.europa.eu/docs/sl_SI/document_library/EPAR_-_Product_Information/human/002041/WC500124085.pdf</uri>
                  </comment>. 
           </mixed-citation>
            </ref>
            <ref id="en-b29">
               <label>29. </label>
               <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <collab>European medicines agency. Science medicines health</collab>.
                    </person-group>.
                    <source>PAssessment report on provisional measures </source>. 
                    <comment>Available from:<uri>https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-assessment-report-provisional-measures_en.pdf</uri>
                  </comment>. 
                </mixed-citation>
            </ref>
            <ref id="en-b30">
               <label>30. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Luyckx</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Squifflet</surname>
                        <given-names>JL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Jadoul</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Votino</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Dolmans</surname>
                        <given-names>MM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Donnez</surname>
                        <given-names>J</given-names>
                     </name>
                    </person-group>. 
                    <article-title>First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids</article-title>. 
                    <source>Fertil Steril</source>. 
                    <year>2014</year>
                    <month>Nov</month>;
                    <volume>102</volume>(
                    <issue>5</issue>):
                    <fpage>1404</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.fertnstert.2014.07.1253</pub-id>
                    <pub-id pub-id-type="pmid">25241376</pub-id>
                    <issn>0015-0282</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b31">
               <label>31. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Monleón</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Martínez-Varea</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Galliano</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Pellicer</surname>
                        <given-names>A</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Successful pregnancy after treatment with ulipristal acetate for uterine fibroids</article-title>. 
                    <source>Case Rep Obstet Gynecol</source>. 
                    <year>2014</year>;
                    <volume>2014</volume>:
                    <fpage>314587</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2014/314587</pub-id>
                    <pub-id pub-id-type="pmid">25143845</pub-id>
                    <issn>2090-6684</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b32">
               <label>32. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Murad</surname>
                        <given-names>K</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Spontaneous pregnancy following ulipristal acetate treatment in a woman with a symptomatic uterine fibroid</article-title>. 
                    <source>J Obstet Gynaecol Can</source>. 
                    <year>2016</year>
                    <month>Jan</month>;
                    <volume>38</volume>(
                    <issue>1</issue>):
                    <fpage>75</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jogc.2015.11.004</pub-id>
                    <pub-id pub-id-type="pmid">26872760</pub-id>
                    <issn>1701-2163</issn>
                </mixed-citation>
            </ref>
         </ref-list>
      </back>
   </sub-article>
</article>
